EP3790879B1 - Triazolopyrimidine compounds and their use in treating cancer - Google Patents

Triazolopyrimidine compounds and their use in treating cancer Download PDF

Info

Publication number
EP3790879B1
EP3790879B1 EP19723404.0A EP19723404A EP3790879B1 EP 3790879 B1 EP3790879 B1 EP 3790879B1 EP 19723404 A EP19723404 A EP 19723404A EP 3790879 B1 EP3790879 B1 EP 3790879B1
Authority
EP
European Patent Office
Prior art keywords
methyl
triazolo
pyrrolidin
trimethyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP19723404.0A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3790879A1 (en
Inventor
Frederick Woolf Goldberg
Attilla Kuan Tsuei TING
Gillian Mcgregor LAMONT
David Buttar
Jason Grant Kettle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dizal Jiangsu Pharmaceutical Co Ltd
Original Assignee
Dizal Jiangsu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizal Jiangsu Pharmaceutical Co Ltd filed Critical Dizal Jiangsu Pharmaceutical Co Ltd
Priority to EP22181542.6A priority Critical patent/EP4134368A1/en
Publication of EP3790879A1 publication Critical patent/EP3790879A1/en
Application granted granted Critical
Publication of EP3790879B1 publication Critical patent/EP3790879B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the specification generally relates to triazolopyrimidine compounds and pharmaceutically acceptable salts thereof. These compounds and their pharmaceutically acceptable salts selectively inhibit MCT4, and the specification therefore also relates to the use of such compounds and salts thereof to treat or prevent MCT4 mediated disease, including cancer.
  • the specification further relates to crystalline forms of triazolopyrimidine compounds and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; and to methods of treating MCT4 mediated disease, including cancer, using such compounds and salts.
  • the references to methods of treatment in the subsequent paragraphs of this description are to be interpreted as references to the compounds or pharmaceutical compositions of the present invention for use in a method for treatment of the human (or animal) body by therapy.
  • Monocarboxylate transporters are encoded by the SLC16 gene family.
  • the family is also known as the monocarboxylate transporter (MCT) family since the first members to be identified were demonstrated to be responsible for the proton-linked transport of monocarboxylates such as L-lactate, pyruvate and ketone bodies across the plasma membrane.
  • MCT1 SLC16A1
  • MCT2 SLC16A7
  • MCT3 SLC16A8
  • MCT4 SLC16A3
  • CD147 acts as an essential chaperone to take MCT1 and MCT4 to the plasma membrane where the transporter and CD147 remain tightly associated ( Kirk et al. (2000) EMBO J. 19: 3896-3904 ).
  • Correct plasma membrane expression of MCT2 shows a strong preference for embigin over CD147 ( Wilson et al (2005) J. Biol. Chem. 280: 27213-27221 ).
  • tumours display altered metabolism ( Vander Heiden (2011) Nat. Drug Dis. 10:671-684 ).
  • Tumours are composed of well oxygenated (aerobic) and poorly oxygenated (hypoxic) regions.
  • tumour cells Compared to normal cells, tumour cells have an increased dependency on the glycolytic pathway for ATP generation either via aerobic glycolysis (the Warburg effect) or anaerobic glycolysis as a consequence of tumour hypoxia.
  • Highly proliferating tumours and hypoxic tumours appear to be particularly dependent upon glycolysis to meet their energy and biosynthetic requirements.
  • FDG-PET Fluorodeoxyglucose Positron Emission Tomography
  • F-18 fluorodeoxyglucose_(FDG) tracer fluorine-18 fluorodeoxyglucose_(FDG)
  • FDG-PET can be used for diagnosis, staging, and monitoring treatment of cancers.
  • FDG-PET combined with computer tomography has a >90% sensitivity and specificity for the detection of metastases of most epithelial tumours ( Mankoff et al. (2007) Clin. Cancer Res. 13:3460-3469 ).
  • a by-product of the increased glycolytic rates in tumours is the accumulation of lactate.
  • Intracellular lactate can be transported out of tumour cells via the monocarboxylate transporters (MCTs 1, 2, 3 & 4) ( Halestrap and Price, Biochem J. (1999) 343; 291-299 ).
  • Lactate that is produced by tumour cells can be taken up by stromal and oxygenated tumour cells ( via the monocarboxylate transporters MCT1 and MCT2) to regenerate pyruvate that can be used to fuel oxidative phosphorylation (OXPHOS) ( Koukouris et al., Cancer Res. (2006) 66; 632-637 ; Sonveaux et al., J. Clin. Invest. (2008) 118; 3930-3942 ).
  • MCT4 hypoxia-inducible factor
  • MCT4 is a HIF target gene and is up-regulated by hypoxia and is required to export lactate from glycolytic tumours ( Ullah et al. (2006) J. Biol. Chem. 281:9030-9037 ).
  • the kinetic properties of MCT4 are tuned to its role in exporting lactic acid derived from glycolysis because its very high Km for pyruvate (150 mM) ensures that pyruvate is not exported from the cell. This is essential because NADH derived from reduction of pyruvate to lactate is required to drive glycolytic flux ( Halestrap and Wilson (2012) IUMBM Life 64: 109-119 ).
  • MCT4 is over-expressed in a range of solid tumours compared to normal epithelium including renal tumours ( Fisel et al. (2013) Clin. Cancer Res. 19: 5170-5181 ; Gerlinger et al. J. Pathol. 227: 146-156 ), pancreatic tumours ( Baek et al. (2014) Cell Rep. 9:2233-2249 ), colorectal tumours ( Pinheiro et al., Virchows Arch. (2008) 452; 139-146 ), HNSCC ( Zhu et al. (2014) PLoS One 9:e87904 ), breast cancer ( Doyen et al. (2014) Biochem. Biophys. Res. Commun. 451:54-61 ), prostate cancer ( Pertega-Gomes et al. BMC Cancer (2011) 11:312 ) and liver cancer ( Gao et al. (2015) J Cancer Res. 141: 1151-1162 ).
  • lactate plays an important role in regulating immune cell function. Lactate has been shown to inhibit the activity of immune effector cells such as T cells and NK cells. Lactic acid suppresses the proliferation and activation of human T cells ex vivo ( Fisher et al. (2007) Blood 109:3812-3819 ; Haas et al. (2015) PLoS Biol 13 ). Husain et al. have demonstrated that NK cells from LDHA-depleted tumours showed improved cytolytic function and lactate treatment of NK cells reduced their cytotoxic activity ( Husain et al. (2013) J. Immunol. 191:1486-1495 ). Furthermore, Brand et al.
  • Lactate accumulation in the tumour microenvironment is accompanied by acidosis (due to the co-transport with protons).
  • a low pH in the tumour microenvironment has been associated with extracellular matrix degradation and migration of tumour cells ( Gillies and Gatenby (2015) Cancer J. 21: 88-96 ).
  • MCT-1/4 inhibitors have been disclosed in WO2017/196936 .
  • composition which comprises a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
  • This specification also describes, in part, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use in therapy.
  • This specification also describes, in part, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer.
  • This specification also describes, in part, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of cancer.
  • This specification also describes, in part, a method for treating cancer in a warm-blooded animal in need of such treatment, which comprises administering to the warm-blooded animal a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
  • heterocycloalkyl means a 5 to 9 membered saturated nitrogen-containing non-aromatic ring (Ring C in Formula (I)) comprising one or more additional heteroatoms independently selected from nitrogen, oxygen and sulphur.
  • suitable heterocycloalkyl groups include morpholinyl, piperazinyl, piperidinyl, thiomorpholinyl, diazabicyclooctanyl, octahydropyrrolo[1,2-a]pyrazinyl, pyrrolidinyl, diazepanyl, oxazepanyl and azepanyl.
  • substituents on the heterocycloalkyl ring may be linked via either a carbon atom or a heteroatom.
  • dioxo means two oxo substituents which are attached to the same atom.
  • dioxo substitution include instances where Ring C represents thiomorpholinyl, where the sulphur atom is substituted with two oxo groups, i.e. where Ring C is thiomorpholine-1,1-dioxide.
  • C 1-3 alkyl includes C 1 alkyl (methyl), C 2 alkyl (ethyl) and C 3 alkyl (propyl as n-propyl and isopropyl).
  • the C 1-3 alkyl is methyl.
  • C p-q alkoxy comprises -O-C p-q alkyl groups.
  • C 1-3 alkoxy includes C 1 alkoxy (methoxy), C 2 alkoxy (ethoxy) and C 3 alkoxy (propoxy as n-propoxy and isopropoxy).
  • the C 1-3 alkoxy is methoxy.
  • substituted means that one or more hydrogens (for example one or two hydrogens, or alternatively one hydrogen) on the designated group is replaced by the indicated substituent(s) (for example one or two substituents, or alternatively one substituent), provided that any atom(s) bearing a substituent maintains a permitted valency.
  • Substituent combinations encompass only stable compounds and stable synthetic intermediates. "Stable” means that the relevant compound or intermediate is sufficiently robust to be isolated and have utility either as a synthetic intermediate or as an agent having potential therapeutic utility. If a group is not described as “substituted”, or “optionally substituted”, it is to be regarded as unsubstituted ( i.e. that none of the hydrogens on the designated group have been replaced).
  • pharmaceutically acceptable is used to specify that an object (for example a salt, dosage form, excipient) is suitable for use in patients.
  • object for example a salt, dosage form, excipient
  • pharmaceutically acceptable salts can be found in the Handbook of Pharmaceutical Salts: Properties, Selection and Use , P. H.
  • a further embodiment provides any of the embodiments defined herein (for example the embodiment of claim 1) with the proviso that one or more specific Examples (for instance, one, two or three specific Examples) selected from the group consisting of Examples 1, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86 and 87 is individually disclaimed.
  • one or more specific Examples for instance, one, two or three specific Examples selected from the group consisting of Examples 1, 4, 5, 6, 7, 8, 9, 10, 11, 12,
  • X represents CH 2 . In another embodiment, X represents O.
  • R 1 and R 2 both represent hydrogen. In another embodiment, R 1 and R 2 both represent methyl. In another embodiment, R 1 represents hydrogen and R 2 represents methyl. In one embodiment, R 1 and R 2 both represent hydrogen or R 1 represents hydrogen and R 2 represents methyl.
  • Ring A is selected from phenyl, pyridinyl, pyrazinyl, pyrimidinyl and pyridazinyl.
  • Ring B is selected from phenyl, pyridinyl, pyrazinyl, pyrimidinyl and pyridazinyl.
  • Ring A is attached to the nitrogen of a pyrrolidine ring and to Ring B, and Ring B is attached to Ring A and to the group -C(R 1 R 2 )-Ring C.
  • Ring A and Ring B may be optionally further substituted as defined herein.
  • the pyrrolidine ring and Ring B are in para (i.e. 1,4) orientation on Ring A.
  • Ring A and the group -C(R 1 R 2 )-Ring C are in para (i.e. 1,4) orientation on Ring B.
  • the pyrrolidine ring and Ring B are in para (i.e.
  • orientation on Ring A and Ring A and the group -C(R 1 R 2 )-Ring C are in para (i.e. 1,4) orientation on Ring B.
  • the pyrrolidine ring and Ring B are in para (i.e. 1,4) orientation on Ring A and Ring A and the group -C(R 1 R 2 )-Ring C are in para (i.e. 1,4) orientation on Ring B and Ring A and Ring B are linked to each other via a ring carbon and are linked to the remainder of the molecule via a ring carbon.
  • At least one of Ring A or Ring B is selected from pyridinyl, pyrazinyl, pyrimidinyl and pyridazinyl.
  • Ring A and Ring B are each independently selected from phenyl, pyridazinyl and pyrazinyl. In another embodiment, Ring A and Ring B are each independently selected from phenyl and pyridazinyl. In another embodiment, Ring A is phenyl and Ring B is pyridazinyl. In another embodiment, Ring A is pyrazinyl and Ring B is phenyl.
  • Ring A and Ring B are optionally substituted with one or two substituents selected from C 1-3 alkyl and C 1-3 alkoxy. In one embodiment, Ring A and Ring B are each independently optionally substituted by one substituent selected from C 1-3 alkyl and C 1-3 alkoxy. In one embodiment, Ring A and Ring B are each independently optionally substituted by one substituent selected from methyl and methoxy.
  • Ring C represents a 5 to 7 membered monocyclic saturated heterocycloalkyl ring. In another embodiment, Ring C represents an 8 or 9 membered bicyclic saturated heterocycloalkyl ring.
  • the bicyclic heterocycloalkyl ring may be a bridged or fused bicyclic ring.
  • Ring C is selected from the group consisting of morpholinyl, piperazinyl, piperidinyl, thiomorpholinyl, diazabicyclooctanyl, octahydropyrrolo[1,2-a]pyrazinyl, pyrrolidinyl, diazepanyl, oxazepanyl and azepanyl.
  • Ring C is selected from the group consisting of morpholin-4-yl, piperazin-4-yl, piperidin-1-yl, thiomorpholine-4-yl, 3,8-diazabicyclo[3.2.1]octan-8-yl, octahydropyrrolo[1,2-a]pyrazin-2-yl, pyrrolidine-1-yl, 1,4-diazepan-1-yl, 1,4-oxazepan-4-yl, azepanyl-1-yl.
  • Ring C is morpholinyl or piperazinyl. In one embodiment, Ring C is morpholin-4-yl or piperazin-4-yl.
  • Ring C is morpholinyl. In one embodiment, Ring C is morpholin-4-yl.
  • Ring C is piperazinyl. In one embodiment, Ring C is piperazin-4-yl.
  • Ring C is optionally substituted with one or more (e.g. one, two or three) substituents independently selected from hydroxyl; ethyl optionally substituted with methoxy or hydroxyl; dioxo, C(O)N(Me) 2 , CH 2 C(O)N(Me) 2 , C(O)Me and S(O) 2 Me. In one embodiment, Ring C is substituted with C(O)Me or methyl.
  • substituents independently selected from hydroxyl; ethyl optionally substituted with methoxy or hydroxyl; dioxo, C(O)N(Me) 2 , CH 2 C(O)N(Me) 2 , C(O)Me and S(O) 2 Me.
  • Ring C is substituted with C(O)Me or methyl.
  • Ring C is piperazin-4-yl-ethanone. In another embodiment, Ring C is 4-methyl-1-piperazinyl.
  • a further embodiment provides a compound of Formula (Ia):
  • R 1 and R 2 both represent hydrogen. In another embodiment, R 1 and R 2 both represent methyl. In another embodiment, R 1 represents hydrogen and R 2 represents methyl. In one embodiment, R 1 and R 2 both represent hydrogen or R 1 represents hydrogen and R 2 represents methyl.
  • D, E, G and J each independently represent N or CR 3 , wherein no more than two of D, E, G and J represent N.
  • L, M, Q and R each independently represent N or CR 3 , wherein no more than two of L, M, Q and R represent N.
  • D, E, G and J each independently represent CR 3 .
  • one of D, E, G and J represents N and the remainder each independently represent CR 3 .
  • two of D, E, G and J represent N and the remainder both independently represent CR 3 .
  • L, M, Q and R each independently represent CR 3 .
  • one of L, M, Q and R represents N and the remainder each independently represent CR 3 .
  • two of L, M, Q and R represent N and the remainder both independently represent CR 3 .
  • D, E, G and J each independently represent CR 3 and L, M, Q and R each independently represent N or CR 3 , wherein no more than two of L, M, Q and R represent N.
  • one of D, E, G and J represents N and the remainder each independently represent CR 3 and L, M, Q and R each independently represent N or CR 3 , wherein no more than two of L, M, Q and R represent N.
  • two of D, E, G and J represent N and the remainder both independently represent CR 3 and L, M, Q and R each independently represent N or CR 3 , wherein no more than two of L, M, Q and R represent N.
  • D, E, G and J represent N or CR 3 , wherein no more than two of D, E, G and J represent N and L, M, Q and R each independently represent CR 3 .
  • D, E, G and J represent N or CR 3 , wherein no more than two of D, E, G and J represent N and one of L, M, Q and R represents N and the remainder each independently represent CR 3 .
  • D, E, G and J represent N or CR 3 , wherein no more than two of D, E, G and J represent N and two of L, M, Q and R represent N and the remainder both independently represent CR 3 .
  • D, E, G and J each independently represent CR 3 and L
  • M, Q and R each independently represent CR 3 .
  • D, E, G and J each independently represent CR 3 and one of L, M, Q and R represents N and the remainder each independently represent CR 3 .
  • D, E, G and J each independently represent CR 3 and two of L, M, Q and R represent N and the remainder both independently represent CR 3 .
  • one of D, E, G and J represents N and the remainder each independently represent CR 3 and L, M, Q and R each independently represent CR 3 .
  • one of D, E, G and J represents N and the remainder each independently represent CR 3 and one of L, M, Q and R represents N and the remainder each independently represent CR 3 .
  • one of D, E, G and J represents N and the remainder each independently represent CR 3 and two of L, M, Q and R represent N and the remainder both independently represent CR 3 .
  • two of D, E, G and J represent N and the remainder both independently represent CR 3 and L, M, Q and R each independently represent CR 3 .
  • two of D, E, G and J represent N and the remainder both independently represent CR 3 and one of L, M, Q and R represents N and the remainder each independently represent CR 3 .
  • two of D, E, G and J represent N and the remainder both independently represent CR 3 and two of L, M, Q and R represent N and the remainder both independently represent CR 3 .
  • the ring containing D, E, G and J is a ring selected from phenyl, pyridinyl, pyrazinyl, pyrimidinyl and pyridazinyl. In one embodiment, the ring containing D, E, G and J is a ring selected from phenyl, pyridazinyl and pyrazinyl. In one embodiment, the ring is selected from phenyl and pyridazinyl.
  • the ring containing L, M, Q and R is a ring selected from phenyl, pyridinyl, pyrazinyl, pyrimidinyl and pyridazinyl. In one embodiment, the ring containing L, M, Q and R is a ring selected from phenyl, pyridazinyl and pyrazinyl. In one embodiment, the ring is selected from phenyl and pyridazinyl.
  • the ring containing D, E, G and J is phenyl and the ring containing L, M, Q and R is pyridazinyl. In another embodiment, the ring containing D, E, G and J is pyrazinyl and the ring containing L, M, Q and R is phenyl.
  • the ring containing D, E, G and J and the ring containing L, M, Q and R are each independently optionally substituted with one or two substituents, i.e. where R 3 represents C 1-3 alkyl and C 1-3 alkoxy. In one embodiment, the ring containing D, E, G and J and the ring containing L, M, Q and R are each independently optionally substituted with one substituent, i.e. where R 3 represents C 1-3 alkyl and C 1-3 alkoxy. In one embodiment, the ring containing D, E, G and J and the ring containing L, M, Q and R are each independently optionally substituted with one substituent where R 3 is selected from methyl and methoxy.
  • Ring C represents a 5 to 7 membered monocyclic saturated heterocycloalkyl ring. In another embodiment, Ring C represents an 8 or 9 membered bicyclic saturated heterocycloalkyl ring.
  • the bicyclic heterocycloalkyl ring may be a bridged or fused bicyclic ring.
  • Ring C is selected from the group consisting of morpholinyl, piperazinyl, piperidinyl, thiomorpholinyl, diazabicyclooctanyl, octahydropyrrolo[1,2-a]pyrazinyl, pyrrolidinyl, diazepanyl, oxazepanyl and azepanyl.
  • Ring C is selected from the group consisting of morpholin-4-yl, piperazin-4-yl, piperidin-1-yl, thiomorpholine-4-yl, 3,8-diazabicyclo[3.2.1]octan-8-yl, octahydropyrrolo[1,2-a]pyrazin-2-yl, pyrrolidine-1-yl, 1,4-diazepan-1-yl, 1,4-oxazepan-4-yl, azepanyl-1-yl.
  • Ring C is morpholinyl or piperazinyl. In one embodiment, Ring C is morpholin-4-yl or piperazin-4-yl.
  • Ring C is morpholinyl. In one embodiment, Ring C is morpholin-4-yl. In one embodiment, Ring C is piperazinyl. In one embodiment, Ring C is piperazin-4-yl.
  • Ring C is optionally substituted with one or more (e.g. one, two or three) substituents independently selected from hydroxyl; ethyl optionally substituted with methoxy or hydroxyl; dioxo, C(O)N(Me) 2 , CH 2 C(O)N(Me) 2 , C(O)Me and S(O) 2 Me. In one embodiment, Ring C is substituted with C(O)Me or methyl.
  • substituents independently selected from hydroxyl; ethyl optionally substituted with methoxy or hydroxyl; dioxo, C(O)N(Me) 2 , CH 2 C(O)N(Me) 2 , C(O)Me and S(O) 2 Me.
  • Ring C is substituted with C(O)Me or methyl.
  • Ring C is piperazin-4-yl-ethanone. In another embodiment, Ring C is 4-methyl-1 -piperazinyl.
  • a further embodiment provides a compound of Formula (Ib): or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , X, Ring A, Ring B and Ring C are as defined herein.
  • a further embodiment provides a compound of Formula (Ic): or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , X, D, E, G, J, L, M, Q, R and Ring C are as defined herein.
  • a compound of Formula (I), or a pharmaceutically acceptable salt thereof wherein the compound is ( R )-4-((6-(4-(3-((2,5,7-trimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)oxy)pyrrolidin-1-yl)phenyl)pyridazin-3-yl)methyl)morpholine (also referred to as Compound A).
  • a compound of Formula (I), or a pharmaceutically acceptable salt thereof wherein the compound is ( R )-1-(4-((6-(4-(3-((2,5,7-trimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)oxy)pyrrolidin-1-yl)phenyl)pyridazin-3-yl)methyl)piperazin-1-yl)ethan-1-one.
  • a compound of Formula (I), or a pharmaceutically acceptable salt thereof wherein the compound is ( R )-2,5,7-trimethyl-6-((1-(5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)pyrazin-2-yl)pyrrolidin-3-yl)methyl)-[1,2,4]triazolo[1,5-a]pyrimidine.
  • a compound of Formula (I), or a pharmaceutically acceptable salt thereof wherein the compound is ( R )-4-((6-(4-(3-((2,5,7-trimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)methyl)pyrrolidin-1-yl)phenyl)pyridazin-3-yl)methyl)morpholine.
  • the compound of Formula (I) is in the free base form.
  • solvated forms may be a hydrated form, such as a hemi-hydrate, a mono-hydrate, a di-hydrate, a tri-hydrate or an alternative quantity thereof.
  • the invention encompasses all such solvated and unsolvated forms of compounds of Formula (I), particularly to the extent that such forms possess MCT4 inhibitory activity, as for example measured using the tests described herein.
  • Atoms of the compounds and salts described in this specification may exist as their isotopes.
  • the invention encompasses all compounds of Formula (I) where an atom is replaced by one or more of its isotopes (for example a compound of Formula (I) where one or more carbon atom is an 11 C or 13 C carbon isotope, or where one or more hydrogen atoms is a 2 H or 3 H isotope, or where one or more nitrogen atoms is a 15 N isotope or where one of more oxygen atoms is an 17 O or 18 O isotope).
  • optically active or racemic forms may exist in optically active or racemic forms by virtue of one or more asymmetric carbon atoms.
  • the invention includes any optically active or racemic form of a compound of Formula (I) which possesses MCT4 inhibitory activity, as for example measured using the tests described herein.
  • the synthesis of optically active forms may be carried out by standard techniques of organic chemistry well known in the art, for example by synthesis using optically active materials or by resolution of a racemic form.
  • a compound of Formula (I), or a pharmaceutically acceptable salt thereof which is a single optical isomer being in an enantiomeric excess (% e.e.) of ⁇ 95%, ⁇ 98% or ⁇ 99%.
  • the single optical isomer is present in an enantiomeric excess (% e.e.) of ⁇ 99%.
  • Some of the compounds of Formula (I) may be crystalline and may have more than one crystalline form. It is to be understood that the invention encompasses any crystalline or amorphous form, or mixtures thereof, which possess properties useful in MCT4 inhibitory activity. It is well known how to determine the efficacy of a crystalline or amorphous form by the standard tests described hereinafter.
  • crystalline materials may be analysed using conventional techniques such as, for example, X-ray powder diffraction (hereinafter XRPD) analysis and Differential Scanning Calorimetry (hereinafter DSC).
  • XRPD X-ray powder diffraction
  • DSC Differential Scanning Calorimetry
  • Example 62 exhibits crystallinity and a crystalline form, Form A, has been identified.
  • crystalline form, Form A, of Compound A which has an XRPD pattern substantially the same as the XRPD pattern shown in Figure 1 , measured by CuK ⁇ radiation.
  • DSC analysis shows Compound A, Form A is a high melting solid with an onset of melting at about 210.2°C and a peak at about 213.2°C.
  • the degree of crystallinity is conveniently greater than about 60%, more conveniently greater than about 80%, preferably greater than about 90% and more preferably greater than about 95%. Most preferably the degree of crystallinity is greater than about 98%.
  • an XRPD pattern may be obtained which has one or more measurement errors depending on measurement conditions (such as equipment or machine used).
  • intensities in an XRPD pattern may fluctuate depending on measurement conditions. Therefore it should be understood that Compound A, Form A of the present disclosure is not limited to the crystals that provide XRPD patterns identical to the XRPD pattern shown in Figure 1 , and any crystals providing XRPD patterns substantially the same as that shown in Figure 1 fall within the scope of the present disclosure.
  • a person skilled in the art of XRPD is able to judge the substantial identity of XRPD patterns.
  • a measurement error of a diffraction angle in an X-ray powder diffractogram is approximately plus or minus 0.2° 2-theta, and such degree of a measurement error should be taken into account when considering the XRPD pattern in Figure 1 and when reading Table A. Furthermore, it should be understood that intensities might fluctuate depending on experimental conditions and sample preparation (preferred orientation).
  • the compounds of Formula (I) include one or more chiral centres.
  • a structure or chemical name in this specification does not indicate chirality, the structure or name is intended to encompass any single stereoisomer (i.e. any single chiral isomer) corresponding to that structure or name, as well as any mixture of stereoisomers (e.g. a racemate).
  • any single stereoisomer i.e. any single chiral isomer
  • a racemate any mixture of stereoisomers
  • a single stereoisomer can be obtained by isolating it from a mixtures of isomers (e.g. a racemate) using, for example, chiral chromatographic separation.
  • a single stereoisomer is obtained through direct synthesis from, for example, a chiral starting material.
  • Compounds of Formula (I), where X represents O may for example be prepared by the reaction of a compound of Formula (II): or a salt thereof, with a compound of Formula (III): or a salt thereof, where W is a suitable leaving group, for example Cl, Br, I or OTf, and R 1 , R 2 , Ring A, Ring B and Ring C are as defined in any of the embodiments herein.
  • the reaction is conveniently performed in a suitable solvent (for example 2-methyltetrahydrofuran) in the presence of a base (for example cesium carbonate) and in the presence of a suitable catalyst (for example Ruphos Pd 3 rd Generation) and ligand (for example Ruphos) at a suitable temperature (for example in the range 60°C to 80°C).
  • a suitable solvent for example 2-methyltetrahydrofuran
  • a base for example cesium carbonate
  • a suitable catalyst for example Ruphos Pd 3 rd Generation
  • ligand for example Ruphos
  • the compounds of Formula (I), or pharmaceutically acceptable salt thereof may also be prepared by reaction of a compound of Formula (II), or salt thereof, and a compound of Formula (III), or salt thereof, using standard aromatic substitution conditions, well known to those skilled in the art, for example with a suitable base (for example diisopropylethylamine) in a suitable solvent (for example 1-butanol) at a suitable temperature (for example in the range of 60°C to 120°C).
  • a suitable base for example diisopropylethylamine
  • a suitable solvent for example 1-butanol
  • the compounds of Formula (II) may for example be prepared by the following scheme, Scheme 1: wherein PG is a suitable nitrogen protecting group, for example Boc.
  • Step 1 Performed using a suitable nucleophile (for example benzoic acid) in the presence of a suitable base (for example KOH) in a suitable solvent (for example DMF) at a suitable temperature (for example in the range of 20°C to 50°C).
  • a suitable nucleophile for example benzoic acid
  • a suitable base for example KOH
  • a suitable solvent for example DMF
  • Step 2 Performed using a suitable cyclisation substrate (for example 3-methyl-1 H -1,2,4-triazol-5-amine) in a suitable solvent (for example AcOH) at a suitable temperature (for example in the range of 70°C to 90°C).
  • a suitable cyclisation substrate for example 3-methyl-1 H -1,2,4-triazol-5-amine
  • a suitable solvent for example AcOH
  • Step 3 Performed under standard hydrolysis conditions, well known to those skilled in the art, for example 1M NaOH (aq) in EtOH at RT.
  • Step 4 Performed using standard conditions well known to those skilled in the art.
  • the reaction may be performed using standard Mitsunobu conditions with a suitable alcohol substrate (for example tert -butyl-3-hydroxypyrrolidine-1-carboxylate) with triphenylphosphine and DIAD in THF at RT.
  • a suitable alcohol substrate for example tert -butyl-3-hydroxypyrrolidine-1-carboxylate
  • triphenylphosphine and DIAD in THF at RT.
  • Step 5 Performed using standard deprotection conditions well known to those skilled in the art.
  • PG is Boc the reaction may be performed using 4M HCl in 1,4-dioxane in MeOH at RT.
  • Compounds of Formula (III), where R 1 and R 2 are hydrogen, may for example be prepared by reacting a compound of Formula (IV) or a salt thereof with a suitable chlorinating reagent (for example trichloroisocyanuric acid) in a suitable solvent (for example dichloroethane) followed by reacting with a suitable Ring C based amine (for example morpholine) at a suitable temperature (for example at RT), wherein W is a suitable leaving group, for example Cl, Br, I or OTf, and Ring A, Ring B and Ring C are as defined in any of the embodiments herein.
  • a suitable chlorinating reagent for example trichloroisocyanuric acid
  • a suitable solvent for example dichloroethane
  • W is a suitable leaving group, for example Cl, Br, I or OTf
  • Ring A, Ring B and Ring C are as defined in any of the embodiments herein.
  • Ring A is phenyl and Ring B is pyradazin
  • Compounds of Formula (I), where X represents CH 2 may for example be prepared by the reaction of compounds of Formula (III), or a salt thereof, where R 1 , R 2 , Ring A, Ring B and Ring C are as defined in any of the embodiments herein, with a compound of Formula (V) or salt thereof.
  • the reaction is conveniently performed in a suitable solvent (for example 1,4-dioxane) in the presence of a base (for example cesium carbonate) and in the presence of a suitable catalyst (for example Ruphos Pd 3 rd Generation) and ligand (for example Ruphos) at a suitable temperature (for example 60°C to 90°C).
  • a suitable solvent for example 1,4-dioxane
  • a base for example cesium carbonate
  • a suitable catalyst for example Ruphos Pd 3 rd Generation
  • ligand for example Ruphos
  • the compounds of Formula (V) may for example be prepared by the following scheme, Scheme 2: wherein PG is a suitable nitrogen protecting group, for example Boc and Y is a suitable leaving group, for example Cl, Br, I or OMs.
  • Step 1 Performed using conditions that convert OH into a suitable leaving group, for example if Br is chosen as leaving group then the reaction may be performed using conditions well known to those skilled in the art for example with triphenylphosphine, tetrabromomethane, in DCM in a temperature range of 0°C to RT.
  • Step 2 Performed using a suitable nucleophile (for example pentane-2,4-dione) in the presence of a suitable base (for example potassium carbonate) in a suitable solvent (for example DMF) at a suitable temperature (for example in the range of 60°C to 80°C).
  • a suitable nucleophile for example pentane-2,4-dione
  • a suitable base for example potassium carbonate
  • a suitable solvent for example DMF
  • Step 3 Performed using a suitable cyclisation substrate (for example 3-methyl-1 H -1,2,4-triazol-5-amine) in a suitable solvent (for example AcOH) at a suitable temperature (for example in the range of (70°C to 90°C).
  • a suitable cyclisation substrate for example 3-methyl-1 H -1,2,4-triazol-5-amine
  • a suitable solvent for example AcOH
  • Step 4 Performed using standard deprotection conditions well known to those skilled in the art.
  • PG is Boc the reaction may be performed using 4M HCl in 1,4-dioxane in MeOH at RT.
  • compounds of Formula (I), where X represents CH 2 may be prepared by reacting a compound of Formula (VI) or salt thereof, where W is a suitable leaving group, for example Cl, Br, I or OTf and Ring A is as defined in any of the embodiments herein, with a compound of Formula (VII) or salt thereof, where Z is a suitable leaving group, for example, pinacol boronate ester, boronic acid or organotin and R 1 , R 2 , Ring B and Ring C are as defined in any of the embodiments herein.
  • R 1 and R 2 represent hydrogen
  • Ring A is pyrazinyl
  • Ring B is phenyl
  • Ring C is 4-methyl-1 -piperazinyl.
  • the compounds of Formula (VI), or salt thereof may be prepared by reacting a compound of Formula (V), or salt thereof, with Ring A using standard aromatic substitution chemistry.
  • Ring A will have a suitable leaving group (for example chlorine or bromine) and the reaction is conveniently performed in a suitable solvent (for example 1-butanol) in the presence of a suitable base (for example diisopropylethylamine) at a suitable temperature (for example 60°C to 120°C).
  • a suitable solvent for example 1-butanol
  • a suitable base for example diisopropylethylamine
  • Ring A will have a suitable leaving group (for example chlorine, bromine or iodine) in a suitable solvent (for example 1,4-dioxane) in the presence of a base (for example cesium carbonate) and in the presence of a suitable catalyst (for example Ruphos Pd 3 rd Generation) at a suitable temperature (for example 60°C to 90°C).
  • a suitable leaving group for example chlorine, bromine or iodine
  • a suitable solvent for example 1,4-dioxane
  • a base for example cesium carbonate
  • a suitable catalyst for example Ruphos Pd 3 rd Generation
  • compounds of Formula (I), where X represents CH 2 may be prepared by reaction of a compound with Formula (VIII) or salt thereof, with a suitable Ring C based amine, where Ring A, Ring B and Ring C are as defined in any of the embodiments herein.
  • the reaction may be performed under standard conditions, well known to those skilled in the art, for example with triethylamine in THF at 60°C.
  • compounds of Formula (I), where X represents CH 2 may be prepared by reaction of a compound with Formula (IX) or salt thereof, with a suitable Ring C based amine, where Ring A, Ring B and Ring C are as defined in any of the embodiments herein.
  • the reaction may be performed under standard conditions, well known to those skilled in the art, for example with sodium triacetoxyborohydride, AcOH in DCM at RT.
  • BCECF AM 2',7'-Bis-(2-Carboxyethyl)-5-(and-6)-Carboxyfluorescein, Acetoxymethyl Ester
  • DMSO Dimethyl Sulphoxide
  • FBS Foetal Bovine Serum
  • HBSS Hanks Balanced Salt Solution
  • HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
  • OD Optical Density
  • RPMI Roswell Park Memorial Institute 1640 Medium.
  • IC 50 value the concentration of test compound that inhibited 50 % of biological activity.
  • IC 50 values were calculated using a smart fitting model within the Screener (Genedata AG) analysis package.
  • MCT4 is predominantly expressed in normal skeletal muscle and is upregulated in a range of solid tumours where it has a role in facilitating the efflux of lactate from the cell thereby preventing intracellular acidification. Thus inhibition of MCT4 activity represents a potential therapeutic opportunity in an oncology setting.
  • MCT1 is a closely related monocarboxylate transporter and as such a key selectivity target for MCT4 inhibitors. Even though MCT4 is primarily involved in cellular efflux of lactate it is possible to drive influx of lactate in an in vitro system as described for assay systems (b) and (d) below.
  • lactic acid present in the media was quantified via a commercial lactate detection kit (Trinity Biotech #735-10) employing the following coupled-enzymatic principle: Lactic acid is converted to pyruvate and H 2 O 2 by lactate oxidase; in the presence of the H 2 O 2 formed, peroxidase catalyzes the oxidative condensation of a chromogen precursor to produce a coloured dye with an absorption maximum at 540 nm (increasing absorbance being directly proportional to increasing lactate within the sample).
  • the absorbance was then measured on an automated microplate reader (PerkinElmer EnVision ) using a 535 nm filter and OD values normalised to control wells - treated with either DMSO (maximum assay signal) or chemistry related to that described in this patent (minimum assay signal) - before fitting concentration response curves to determine an IC 50 value.
  • NCI-H358 cells ATCC CRL-5807 or K562 cells (ATCC CCL-243) were defrosted directly from cryopreservation, washed and re-suspended in HBSS (Gibco #14170) with 1 mM [final] HEPES (Gibco #15630).
  • INS-1 MCT4 cells were generated through transfection of the parental cell background with the following DNA sequence, inserted into a pcDNA3.1 (ThermoFisher #V79020) mammalian expression vector:
  • the resultant cell pool was continually cultured at 37 °C and 5 % CO 2 under antibiotic selection in RPMI (Sigma #R0883) medium containing 1 % L glutamine (Sigma #G7513), 10 % FBS (Sigma #F7524), 10 mM [final] HEPES (Gibco #15630), 0.004 % ⁇ -Mercaptoethanol (Sigma #M6250) and 100 ⁇ g/ml Geneticin (ThermoFisher #10131027). An individual clone was selected and expanded before being cryopreserved in a number of individual vials for continued use.
  • NSCLC cell line NCI H358 can be grown as a subcutaneous xenograft in female nude mice and tumour volume calculated from bilateral caliper measurements.
  • NCI H358 cells were inoculated sub-cutaneously onto the left flank of the animal in a volume of 0.1 ml serum free media (RPMI) and matrigel. Animals were assigned into treatment groups 14 days after cell implantation and received either AZD2171 (3 mg/kg QD) ( Wedge et al., (2005) Cancer Res.
  • Example 62 The results of testing Example 62 are shown in Figure 3 .
  • VEGF inhibitor AZD2171 was effective demonstrating a 33% (p ⁇ 0.001) tumour regression compared to the vehicle group.
  • MCT4 inhibitors of Formula (I) The in vivo efficacy of MCT4 inhibitors has been tested in murine syngeneic models.
  • MCT1 was knocked-out (KO) of the MC38 syngeneic cell line model using CRISPR precise genome editing.
  • the MC38 MCT1 KO murine colorectal cell line can be grown sub-cutaneously in female C57.Bl6 mice and tumour volume calculated from bilateral caliper measurements.
  • ten million cells were inoculated subcutaneously onto the left flank of the animal in a volume of 0.1ml serum free DMEM media. Animals were randomised by bodyweight at the time of cell implantion and treatement started the following day.
  • monotherapy treatment arms received either a compound of Formula (I) (100 mg/kg BID) by oral gavage or ⁇ CTLA4 antibody (anti-CTLA-4 9D9 mlgG1 antibody, described in WO200712373 ) (10 mg/kg twice weekly) intraperitoneally.
  • Combination groups consisted of a compound of Formula (I) (100 or 10 mg/kg PO BID) with aCTLA4 antibody (10 mg/kg IP twice weekly).
  • monotherapy treatment arms received either a compound of Formula (I) (30 mg/kg PO BID) with ⁇ PD-1 antibody (from Bio X Cell, Catalogue # BE0146, Lot 665417s1, 6.78 mg/mL) (10 mg/kg IP twice weekly).
  • ⁇ PD-1 antibody from Bio X Cell, Catalogue # BE0146, Lot 665417s1, 6.78 mg/mL
  • dosing was continued for up to 6 weeks and tumour volume, body weight and tumour condition were recorded three times weekly.
  • Vehicle was 0.5% hydroxy propyl methyl cellulose/0.1% Tween 80 given twice daily by oral gavage with PBS/a given twice weekly intraperitoneally in both studies.
  • Example 62 The results of testing Example 62 in the first syngeneic study are shown in Figure 4 .
  • Individual tumour growth profiles are shown with animals taken off study using time to event criteria based on a maximum tumour volume of 1.5 cm 3 , tumour condition or animal welfare limits. Due to animals coming off study during the later stages of the experiment, GeoMean percentage inhibition values were calculated on Day 15. Compared to vehicle control, Example 62 monotherapy (100 mg/kg) delivered 60.0% p ⁇ 0.05 growth inhibition on that day. Monotherapy aCTLA4 (10 mg/kg) was ineffective with 6.1% NS .
  • spider plots shown in Figures 4 and 5 represent individual animal tumour growth data, comparing vehicle control growth with treatment groups.
  • MCT4 lactate efflux pIC50 (SKBR3) MCT4 FLIPR pIC50 (H358) MCT1 FLIPR pIC50 (K562) MCT4 FLIPR pIC50 (INS-1) 1 9.5 - - - 4 9.2 7.4 - - 5 9.3 7.9 - - 6 9.2 8.1 - - 7 9.5 - - - 8 9.2 7.6 - - 9 9.3 7.8 ⁇ 4.7 - 10 9.3 7.5 - - 11 9.5 8.1 - - 12 8.4 - - - 13 8.6 - - - 14 8.7 - - - 15 9.0 - - - 16 9.3 7.5 - - 17 9.6 - - - 18 9.2 - - - 19 9.7 8.1 - - 20 9.3 7.4 - - 21 8.9 7.7 - - 22 9.0 - - - 23 9.4 8.2 - - 24 9 .
  • Compounds may be further selected on the basis of further biological or physical properties which may be measured by techniques known in the art and which may be used in the assessment or selection of compounds for therapeutic or prophylactic application.
  • the compounds of Formula (I), and pharmaceutically acceptable salts thereof are expected to be useful in therapy.
  • the term “therapy” is intended to have its normal meaning of dealing with a disease in order to entirely or partially relieve one, some or all of its symptoms, or to correct or compensate for the underlying pathology.
  • the term “therapy” also includes “prophylaxis” unless there are specific indications to the contrary.
  • the terms “therapeutic” and “therapeutically” should be interpreted in a corresponding manner.
  • prophylaxis is intended to have its normal meaning and includes primary prophylaxis to prevent the development of the disease and secondary prophylaxis whereby the disease has already developed and the patient is temporarily or permanently protected against exacerbation or worsening of the disease or the development of new symptoms associated with the disease.
  • treatment is used synonymously with “therapy”.
  • treat can be regarded as “applying therapy” where “therapy” is as defined herein.
  • cancer includes both non-metastatic cancer and also metastatic cancer, such that treating cancer involves treatment of both primary tumours and also tumour metastases.
  • the disease mediated by MCT4 is cancer.
  • the cancer is selected from the group consisting of colorectal cancer, glioblastoma, gastric cancer, ovarian cancer, diffuse large B-cell lymphoma, chronic lymphocytic leukaemia, acute myeloid leukaemia, head and neck squamous cell carcinoma, breast cancer, prostate cancer, bladder cancer, hepatocellular carcinoma, renal cancer, thyroid cancer, pancreatic cancer, small cell lung cancer and non-small cell lung cancer.
  • the cancer is non-small cell lung cancer.
  • the cancer is lung adenocarcinoma.
  • a compound of Formula (I), or a pharmaceutically acceptable salt thereof for use in the treatment of cancer.
  • the disease mediated by MCT4 is cancer.
  • the cancer is selected from the group consisting of colorectal cancer, glioblastoma, gastric cancer, ovarian cancer, diffuse large B-cell lymphoma, chronic lymphocytic leukaemia, acute myeloid leukaemia, head and neck squamous cell carcinoma, breast cancer, prostate cancer, bladder cancer, hepatocellular carcinoma, renal cancer, thyroid cancer, pancreatic cancer, small cell lung cancer and non-small cell lung cancer.
  • the cancer is non-small cell lung cancer.
  • the cancer is lung adenocarcinoma.
  • a method for treating a disease in which inhibition of MCT4 is beneficial in a warm-blooded animal in need of such treatment which comprises administering to said warm-blooded animal a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
  • the disease is cancer.
  • the cancer is selected from the group consisting of colorectal cancer, glioblastoma, gastric cancer, ovarian cancer, diffuse large B-cell lymphoma, chronic lymphocytic leukaemia, acute myeloid leukaemia, head and neck squamous cell carcinoma, breast cancer, prostate cancer, bladder cancer, hepatocellular carcinoma, renal cancer, thyroid cancer, pancreatic cancer, small cell lung cancer and non-small cell lung cancer.
  • the cancer is non-small cell lung cancer.
  • the cancer is lung adenocarcinoma.
  • a method for treating cancer in a warm-blooded animal in need of such treatment which comprises administering to said warm-blooded animal a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
  • Tumours that selectively express MCT4 over MCT1 have an increased likelihood of responding to treatment with a MCT4 inhibitor. Therefore, patients whose tumours express MCT1 at a low level are likely to respond better to an MCT4 inhibitor than those patients whose tumours express MCT1 at a higher level. Generally, patients whose tumours have a high MCT4:MCT1 expression ratio (due to the low level of MCT1 expression), are likely to show a better response, so evaluating the relative expression levels of both MCT1 and MCT4 provides a means for selecting patients for treatment with a MCT4 inhibitor. Methods for determining the relative expression levels of MCT1 and MCT4 are known in the art and are described in WO2010/089580 .
  • a method of treating cancer comprising (i) testing a tumour sample obtained from a patient suffering from or likely to suffer from cancer for selective expression of MCT4 over MCT1 and (ii) administering to the patient having the tumour which selectively expresses MCT4 over MCT1, a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
  • a compound of Formula (I), or a pharmaceutically acceptable salt thereof for use in the treatment of cancer in a patient wherein the cancer tumour selectively expresses MCT4 over MCT1.
  • a compound of Formula (I), or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of cancer in a patient wherein the cancer tumour selectively expresses MCT4 over MCT1.
  • a method for treating cancer in a warm-blooded animal in need of such treatment which comprises administering to said warm-blooded animal a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the cancer tumour selectively expresses MCT4 over MCT1.
  • therapeutically effective amount refers to an amount of a compound of Formula (I) as described in any of the embodiments herein which is effective to provide "therapy” in a subject, or to “treat” a disease or disorder in a subject.
  • the therapeutically effective amount may cause any of the changes observable or measurable in a subject as described in the definition of "therapy", “treatment” and “prophylaxis” above.
  • the effective amount can reduce the number of cancer or tumour cells; reduce the overall tumour size; inhibit or stop tumour cell infiltration into peripheral organs including, for example, the soft tissue and bone; inhibit and stop tumour metastasis; inhibit and stop tumour growth; relieve to some extent one or more of the symptoms associated with the cancer; reduce morbidity and mortality; improve quality of life; or a combination of such effects.
  • An effective amount may be an amount sufficient to decrease the symptoms of a disease responsive to inhibition of MCT4 activity.
  • efficacy in vivo can, for example, be measured by assessing the duration of survival, time to disease progression (TTP), the response rates (RR), duration of response, and/or quality of life.
  • effective amounts may vary depending on route of administration, excipient usage, and co-usage with other agents.
  • the amount of the compound of Formula (I) or pharmaceutically acceptable salt described in this specification and the amount of the other pharmaceutically active agent(s) are, when combined, jointly effective to treat a targeted disorder in the animal patient.
  • the combined amounts are in a "therapeutically effective amount” if they are, when combined, sufficient to decrease the symptoms of a disease responsive to inhibition of MCT4 activity as described above.
  • such amounts may be determined by one skilled in the art by, for example, starting with the dosage range described in this specification for the compound of Formula (I) or pharmaceutically acceptable salt thereof and an approved or otherwise published dosage range(s) of the other pharmaceutically active compound(s).
  • Warm-blooded animals include, for example, humans.
  • the anti-cancer treatment described in this specification may be useful as a sole therapy, or may involve, in addition to administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, conventional surgery, radiotherapy or chemotherapy; or a combination of such additional therapies.
  • Such conventional surgery, radiotherapy or chemotherapy may be administered simultaneously, sequentially or separately to treatment with the compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • a combination therapy is administered "simultaneously" this includes treatment of a patient with a single dosage form (e.g. a tablet) comprising both a compound of Formula (I), or a pharmaceutically acceptable salt thereof and an additional anti-cancer substance; and also simultaneous dosing of separate dosage forms each separately comprising one of the respective combination partners.
  • a single dosage form e.g. a tablet
  • simultaneous dosing of separate dosage forms each separately comprising one of the respective combination partners.
  • a combination therapy is administered "sequentially” or “separately"
  • this includes treatment of a patient with a first dosage form (e.g. a tablet) comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, followed by treatment of the same patient with a second dosage form comprising an additional anti-cancer substance; or treatment of a patient with a single dosage form (e.g. a tablet) comprising a particular anti-cancer substance, followed by treatment of the same patient with a second dosage form comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
  • the interval between the sequential or separate doses may be judged by a skilled practitioner with reference to the information in this specification.
  • a compound of Formula (I), or a pharmaceutically acceptable salt thereof for use in the treatment of cancer, where the compound of Formula (I), or a pharmaceutically acceptable salt thereof is administered before surgery.
  • Administration of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, before surgery to entirely or partially remove a cancer may be referred to as "neo-adjuvant therapy".
  • the goal of administering the compound of Formula (I), or a pharmaceutically acceptable salt thereof is generally to reduce the size of the target tumour in order to increase the chances of a successful resection.
  • the length of time the compound of Formula (I), or a pharmaceutically acceptable salt thereof is dosed before surgery may be judged by a skilled practitioner with reference to the information within this specification.
  • a compound of Formula (I), or a pharmaceutically acceptable salt thereof for use in the treatment of cancer, where the compound of Formula (I), or a pharmaceutically acceptable salt thereof is administered after surgery.
  • a compound of Formula (I), or a pharmaceutically acceptable salt thereof for use in the treatment of cancer, where the compound of Formula (I), or a pharmaceutically acceptable salt thereof is administered in combination with at least one additional anti-cancer substance.
  • a compound of Formula (I), or a pharmaceutically acceptable salt thereof for use in the treatment of cancer, where the compound of Formula (I), or a pharmaceutically acceptable salt thereof is administered simultaneously, sequentially or separately with at least one additional anti-cancer substance.
  • anti-cancer treatment may be applied as a sole therapy or may involve, in addition to the compounds of the specification, conventional surgery or radiotherapy or chemotherapy.
  • Such chemotherapy may include one or more of the following categories of anti-tumour agents:
  • a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and at least one additional anti-tumour substance, for use in the treatment of cancer In one embodiment there is provided a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, where the compound of Formula (I), or a pharmaceutically acceptable salt thereof is administered in combination with an additional anti-tumour substance. In one embodiment there is one additional anti-tumour substance. In one embodiment there are two additional anti-tumour substances. In one embodiment there are three or more additional anti-tumour substances.
  • a compound of Formula (I), or a pharmaceutically acceptable salt thereof and at least one additional anti-tumour substance for use in the simultaneous, separate or sequential treatment of cancer.
  • a method of treating cancer in a warm-blooded animal who is in need of such treatment which comprises administering to said warm-blooded animal a compound of Formula (I), or a pharmaceutically acceptable salt thereof and at least one additional anti-tumour substance, wherein the amounts of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and the additional anti-tumour substance are jointly effective in producing an anti-cancer effect.
  • a method of treating cancer in a warm-blooded animal who is in need of such treatment which comprises administering to said warm-blooded animal a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and simultaneously, separately or sequentially administering at least one additional anti-tumour substance to said warm-blooded animal, wherein the amounts of the compound of Formula (I), or pharmaceutically acceptable salt thereof, and the additional anti-tumour substance are jointly effective in producing an anti-cancer effect.
  • the additional anti-tumour substance is selected from the group consisting of one or more of the anti-tumour substances listed under points (i) - (v) above.
  • PD-1 antibodies e.g. nivolumab and pembrolizumab
  • PD-L1 antibodies e.g. durvalumab and atezolizumab
  • CTLA4 antibodies e.g. tremelimumab and ipilimumab
  • CD73 antibodies e.g. oleclumab
  • PD-L1 antibodies e.g. durvalumab and atezolizumab
  • the cancer is non-small cell lung cancer. In one embodiment, the cancer is lung adenocarcinoma.
  • a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer where the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered simultaneously, separately or sequentially with at least one additional anti-tumour substance selected from the group consisting of PD-1 antibodies (e.g. nivolumab and pembrolizumab), PD-L1 antibodies (e.g. durvalumab and atezolizumab), CTLA4 antibodies (e.g. tremelimumab and ipilimumab), CD73 antibodies (e.g. oleclumab), CD40 ligand fusion proteins and GITR ligand fusion proteins.
  • PD-1 antibodies e.g. nivolumab and pembrolizumab
  • PD-L1 antibodies e.g. durvalumab and atezolizumab
  • CTLA4 antibodies e.g. tremelimumab and ipilimumab
  • a compound of Formula (I), or a pharmaceutically acceptable salt thereof for use in the treatment of cancer, where the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered simultaneously, separately or sequentially with at least one additional anti-tumour substance selected from the group consisting of PD-L1 antibodies (e.g. durvalumab and atezolizumab).
  • PD-L1 antibodies e.g. durvalumab and atezolizumab
  • a compound of Formula (I), or a pharmaceutically acceptable salt thereof for use in the treatment of cancer, where the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered simultaneously, separately or sequentially with durvalumab.
  • the cancer is non-small cell lung cancer. In one embodiment, the cancer is lung adenocarcinoma.
  • a compound of Formula (I), or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of cancer, where the compound of Formula (I), or a pharmaceutically acceptable salt thereof is administered simultaneously, separately or sequentially with at least one additional anti-tumour substance selected from the group consisting of PD-1 antibodies (e.g. nivolumab and pembrolizumab), PD-L1 antibodies (e.g. durvalumab and atezolizumab), CTLA4 antibodies (e.g. tremelimumab and ipilimumab), CD73 antibodies (e.g. oleclumab), CD40 ligand fusion proteins and GITR ligand fusion proteins.
  • PD-1 antibodies e.g. nivolumab and pembrolizumab
  • PD-L1 antibodies e.g. durvalumab and atezolizumab
  • CTLA4 antibodies e.g. tremelimumab and ipilim
  • a compound of Formula (I), or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of cancer, where the compound of Formula (I), or a pharmaceutically acceptable salt thereof is administered simultaneously, separately or sequentially with at least one additional anti-tumour substance selected from the group consisting of PD-L1 antibodies (e.g. durvalumab and atezolizumab).
  • PD-L1 antibodies e.g. durvalumab and atezolizumab
  • a compound of Formula (I), or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of cancer, where the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered simultaneously, separately or sequentially with durvalumab.
  • the cancer is non-small cell lung cancer. In one embodiment the cancer is lung adenocarcinoma.
  • a method for treating cancer in a warm-blooded animal in need of such treatment which comprises administering to said warm-blooded animal a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, simultaneously, separately or sequentially with at least one additional anti-tumour substance selected from the group consisting of PD-1 antibodies (e.g. nivolumab and pembrolizumab), PD-L1 antibodies (e.g. durvalumab and atezolizumab), CTLA4 antibodies (e.g. tremelimumab and ipilimumab), CD73 antibodies (e.g. oleclumab), CD40 ligand fusion proteins and GITR ligand fusion proteins.
  • PD-1 antibodies e.g. nivolumab and pembrolizumab
  • PD-L1 antibodies e.g. durvalumab and atezolizumab
  • CTLA4 antibodies e.g. tremelim
  • a method for treating cancer in a warm-blooded animal in need of such treatment which comprises administering to said warm-blooded animal a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, simultaneously, separately or sequentially with at least one additional anti-tumour substance selected from the group consisting of PD-L1 antibodies (e.g. durvalumab and atezolizumab).
  • a method for treating cancer in a warm-blooded animal in need of such treatment which comprises adiminstering to said warm-blooded animal a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, simultaneously, separately or sequentially with durvalumab.
  • the cancer is non-small cell lung cancer. In one embodiment the cancer is lung adenocarcinoma.
  • a pharmaceutical composition comprising a compound of Formula (I) and at least one additional anti-tumour substance, for use in the treatment of cancer.
  • the pharmaceutical composition also comprises at least one pharmaceutically acceptable excipient.
  • the anti-tumour substance is an anti-neoplastic agent.
  • the compounds of Formula (I), and pharmaceutically acceptable salts thereof, may be administered as pharmaceutical compositions, comprising one or more pharmaceutically acceptable excipients.
  • compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
  • the compositions may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous or intramuscular dosing), or as a suppository for rectal dosing.
  • the compositions may be obtained by conventional procedures using conventional pharmaceutical excipients, well known
  • a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, for use in therapy.
  • a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, for use in the treatment of cancer.
  • said cancer is selected from the group consisting of colorectal cancer, glioblastoma, gastric cancer, ovarian cancer, diffuse large B-cell lymphoma, chronic lymphocytic leukaemia, acute myeloid leukaemia, head and neck squamous cell carcinoma, breast cancer, prostate cancer, bladder cancer, hepatocellular carcinoma, renal cancer, thyroid cancer, pancreatic cancer, small cell lung cancer and non-small cell lung cancer.
  • the cancer is non-small cell lung cancer.
  • the cancer is lung adenocarcinoma.
  • the compound of Formula (I) will normally be administered to a warm-blooded animal at a unit dose within the range 2.5-5000 mg/m 2 body area of the animal, or approximately 0.05-100 mg/kg, and this normally provides a therapeutically-effective dose.
  • a unit dose form such as a tablet or capsule will usually contain, for example 0.1-500 mg of active ingredient.
  • the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, any therapies being co-administered, and the severity of the illness being treated.
  • NMR spectra were obtained at 500 MHz in d6-dimethylsulfoxide.
  • the following abbreviations have been used (and derivatives thereof, e.g. dd, doublet of doublets, etc.): s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad; qn, quintet; p, pentet (vi) unless stated otherwise compounds containing an asymmetric carbon and/or sulfur atom were not resolved; (vii) intermediates were not necessarily fully purified but their structures and purity were assessed by TLC, analytical HPLC/UPLC, and/or NMR analysis and/or mass spectrometry; (viii) unless otherwise stated, flash column chromatography (fcc) was performed on Merck Kieselgel silica (Art.
  • a typical 2 minute analytical UPLC method would employ a solvent gradient over 1.3 minutes, at approximately 1 mL per minute, from a 97:3 mixture of solvents A and B respectively to a 3:97 mixture of solvents A and B.
  • (xii) where reactions refer to the use of a microwave, one of the following microwave reactors were used: Biotage Initiator, Personal Chemistry Emrys Optimizer, Personal Chemistry Smithcreator or CEM Explorer;
  • a chiral stationary phase such as a cellulose or amylose chiral Daicel column or equivalent was chosen to optimise separation of isomers within the sample.
  • Semi preparative separations typically used a chiral column with dimensions 30 x 250 mm, 5 micron with SFC flow rates of 100 ml/min or HPLC flow rate of 40 ml/min.
  • Detection was by UV absorbance or mass spectrometric detection.
  • a generic wavelength typically 220nm or 254 nm, was used or a wavelength was chosen to maximise the product response.
  • mass detection a soft ionization technique such as electrospray ionization was employed allowing the product to be detected by targeting MH+ response.
  • Detection was by UV absorbance (DAD) and/or mass spectrometry (full scan).
  • DAD UV absorbance
  • full scan mass spectrometry
  • the sample was dissolved in a compatible solvent at a concentration of approximately 0.5 mg/ml and injected directly into the chromatographic system.
  • column temperature was held constant at approximately 40°C and back pressure regulated to a constant pressure of approximately 100-150 bar.
  • the X-ray powder diffractogram was determined by mounting a sample of the crystalline material on a Bruker single silicon crystal (SSC) wafer mount and spreading out the sample into a thin layer with the aid of a microscope slide. The sample was spun at 30 revolutions per minute (to improve counting statistics) and irradiated with X-rays generated by a copper long-fine focus tube operated at 40 kV and 40 mA with a wavelength of 1.5418 angstroms. The collimated X-ray source was passed through an automatic variable divergence slit set at V20 and the reflected radiation directed through a 5.89 mm anti scatter slit and a 9.55 mm detector slit.
  • SSC Bruker single silicon crystal
  • Samples were measured in reflection geometry in ⁇ - 2 ⁇ configuration over the scan range 2° to 40° 2 ⁇ with a nominal 0.12 second exposure per 0.02° increment.
  • the instrument was equipped with a Position sensitive detector (Lynxeye).
  • Position sensitive detector Lixeye
  • the relative intensity of peaks can be affected by, for example, grains above 30 microns in size and non-unitary aspect ratios that may affect analysis of samples.
  • the skilled person will also understand that the position of reflections can be affected by the precise height at which the sample sits in the diffractometer and the zero calibration of the diffractometer. The surface planarity of the sample may also have a small effect.
  • Triphenylphosphine (78 g, 298.1 mmol) was added portionwise to ( R ) -tert -butyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate (50 g, 248.4 mmol) and CBr 4 (115 g, 347.8 mmol) in DCM (1 L) at 0°C over a period of 5 min.
  • 6-Bromonicotinaldehyde (3 g, 16.13 mmol) and 1-methylpiperazine (4.85 g, 48.39 mmol) were stirred in DCM (200 mL) at rt for 2 h.
  • AcOH (0.097 g, 1.61 mmol) and sodium triacetoxyborohydride (6.84 g, 32.26 mmol) were added and the mixture was stirred at rt for 16 h.
  • the reaction mixture was quenched with sat. aq. NaHCO 3 and the organic layer was separated.
  • the aquoues layer was extracted with EtOAc and the combined organic layers were dried (Na 2 SO 4 ), filtered and concentrated in vacuo.
  • PdCl 2 (dppf) (21.67 mg, 0.03 mmol) was added to 1-((5-bromopyridin-2-yl)methyl)-4-methylpiperazine (160 mg, 0.59 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (165 mg, 0.65 mmol) and potassium acetate (116 mg, 1.18 mmol) in 1,4-dioxane (4 mL) at rt under nitrogen. The resulting mixture was stirred at 90 °C for 16 h.
  • 1,3,5-Trichloro-1,3,5-triazinane-2,4,6-trione (1.808 g, 7.78 mmol) was added in one portion to 3-chloro-6-methylpyridazine (2.00 g, 15.56 mmol) in DCE (100 mL) at rt.
  • the reaction mixture was stirred at 60°C for 2 h, then was allowed to cool to rt and filtered.
  • Morpholine (0.86 mL, 9.82 mmol) was added in one portion to 3-chloro-6-(chloromethyl)pyridazine (1.6 g, 9.82 mmol) and DIPEA (2.05 mL, 11.8 mmol) in THF (16 mL) at rt.
  • the reaction mixture was stirred at rt for 3 days, then was filtered and washed with THF.
  • PdCl 2 (dppf)-CH 2 Cl 2 adduct (92 mg, 0.13 mmol) was added to 4-bromo-3-methylbenzaldehyde (500 mg, 2.51 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (638 mg, 2.51 mmol) and potassium acetate (493 mg, 5.02 mmol) in 1,4-dioxane (10 mL) at rt. The reaction mixture was stirred at 90°C for 16 h, then was allowed to cool to rt and was concentrate in vacuo.
  • HATU (3.74 g, 9.82 mmol) was added to 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)acetic acid (2 g, 8.19 mmol) in DMF (25 mL) at rt under air and the reaction mixture was stirred at rt for 30 min.
  • Dimethylamine (12.28 mL, 24.56 mmol) and DIPEA (4.29 mL, 24.56 mmol) were added to the mixture at rt under air.
  • the reaction mixture was stirred at rt for 2 h and then poured into sat. aq. NaHCO 3 (200 mL) and extracted with EtOAc (3 ⁇ 100 mL).
  • N , N -dimethyl-2-(piperazin-1-yl)acetamide dihydrochloride 800 mg, 3.28 mmol was added to 4-bromobenzaldehyde (606 mg, 3.28 mmol) in THF (25 mL) at rt under air and the reaction mixture was stirred at rt for 3 h.
  • Sodium triacetoxyborohydride 1389 mg, 6.55 mmol
  • AcOH (2 drops
  • Pd(Ph 3 P) 4 (578 mg, 0.50 mmol) was added to 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)morpholine (1516 mg, 5.00 mmol), 5-bromo-2-iodopyrimidine (1424 mg, 5 mmol) and Na 2 CO 3 (1060 mg, 10.00 mmol) in toluene (20 mL) and water (4 mL), and the reaction mixture was stirred at 120°C for 3 days, then allowed to cool to rt and concentrated in vacuo. The residue was taken up in EtOAc (100 mL) and washed sequentially with water (2 ⁇ 20 mL).
  • Potassium iodide (152 mg, 0.91 mmol) was added to 5-(bromomethyl)-2-(4-bromophenyl)pyrimidine (300 mg, 0.91 mmol), 1-methylpiperazine (82 mg, 0.82 mmol) and K 2 CO 3 (126 mg, 0.91 mmol) in DMF (10 mL) under air. The resulting mixture was stirred at rt for 2 h. The solvent was removed in vacuo.
  • Pd(Ph 3 P) 4 (0.389 g, 0.34 mmol) was added to tert -butyl 4-((6-bromopyridin-3-yl)methyl)piperazine-1-carboxylate (2.40 g, 6.74 mmol), (4-bromophenyl)boronic acid (1.35 g, 6.74 mmol) and potassium carbonate (2.79 g, 20.2 mmol) in degassed 1,4-dioxane (12 mL) and water (3 mL) at rt. The reaction mixture was heated at 85°C in a microwave reactor for 3 h, then was allowed to cool to rt and diluted with EtOAc.
  • Pd(Ph 3 P) 4 (179 mg, 0.15 mmol) was added to 4-((5-bromopyrimidin-2-yl)methyl)morpholine (400 mg, 1.55 mmol), (4-bromophenyl)boronic acid (311 mg, 1.55 mmol) and Na 2 CO 3 (328 mg, 3.10 mmol) in 1,4-dioxane (5 mL) and water (2.5 mL) at rt. The reaction mixture was stirred at 80°C for 16 h, then was allowed to cool to rt and concentrated in vacuo.
  • Triphenylphosphine (5.53 ml, 23.9 mmol) was added portionwise to (4-bromo-3-methoxyphenyl)methanol (4.32 g, 20.0 mmol) and carbon tetrabromide (7.26 g, 21.9 mmol) in DCM (100 ml) at 0°C over a period of 2 min. The reaction mixture was allowed to warm to rt and was stirred at rt for 18 h, then was concentrated in vacuo.
  • Triethylamine (2.10 mL, 15.1 mmol) was added to ( R )-2,5,7-trimethyl-6-(pyrrolidin-3-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrimidine dihydrochloride (1.2 g, 3.77 mmol) and 2,6-dichloropyrazine (0.562 g, 3.77 mmol) in n -propanol (20 mL). The reaction mixture was stirred at 90°C for 16 h, then was allowed to cool to rt and concentrate in vacuo. Water (50 mL) was added to the residue and was extracted with EtOAc (3 ⁇ 50 mL).
  • NBS 0.527 g, 2.96 mmol
  • ( R )-2,5,7-trimethyl-6-((1-(6-methylpyrazin-2-yl)pyrrolidin-3-yl)methyl)-[1,2,4]triazolo[1,5-a]pyrimidine (1 g, 2.96 mmol) in DCM (10 mL) at 0°C under air.
  • the reaction mixture was stirred at 0°C for 1 h, then water was added (25 mL) and the mixture was extracted with DCM (3 ⁇ 25 mL). The combined organic layers were dried over Na 2 SO 4 , filtered and concentrated in vacuo.
  • reaction mixture was allowed to warm to rt and was stirred at rt for 3 h, then was diluted with DCM (50 mL) and adjusted to pH 8-9 with Na 2 CO 3 (2 M aq solution). The organic layer was isolated and washed with sat. brine, passed through a phase separating cartridge and concentrated in vacuo to afford the title compound (181 mg, 87%) as a yellow solid which was used without further purification; m / z MH + 448.
  • Triethylamine (1.75 mL, 12.6 mmol) was added to ( R )-2,5,7-trimethyl-6-(pyrrolidin-3-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrimidine dihydrochloride (1 g, 3.14 mmol), 3,6-dichloropyridazine (0.468 g, 3.14 mmol) in n -propanol (10 mL) at rt under air. The reaction mixture was stirred at 90°C for 16 h, then allowed to cool to rt and partially concentrated in vacuo.
  • 2,4-Dioxopentan-3-yl benzoate (58 g, 263 mmol) was added to 3-methyl-1H-1,2,4-triazol-5-amine (27.1 g, 277 mmol) in AcOH (300 mL) at rt.
  • the reaction mixture was stirred at 90°C for 10 h, then was allowed to cool to rt, concentrated in vacuo and adjusted to pH>7 with sat. aq. NaHCO 3 .
  • the mixture was extracted with EtOAc (3 ⁇ 500 mL). The combined organic layers were washed with sat.
  • Diisopropyl azodicarboxylate (52.4 mL, 269 mmol) was added dropwise to 2,5,7-trimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-6-ol (40 g, 224 mmol), tert -butyl ( S )-3-hydroxypyrrolidine-1-carboxylate (46.2 g, 247 mmol) and triphenylphosphine (70.7 g, 269 mmol) in THF (800 mL) at rt over a period of 2 h, and the reaction mixture was stirred at rt for 10 min and concentrated in vacuo.
  • 1,3,5-Trichloro-1,3,5-triazinane-2,4,6-trione (20.4 g, 87.8 mmol) was added portionwise to 3-(4-bromophenyl)-6-methylpyridazine (Intermediate 64) (50 g, 200.7 mmol) in DCM (600 mL) at rt.
  • the reaction mixture was stirred at rt for 1 h then a further portion of 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione (0.7g) was added and the reaction mixture was stirred for 30 min, then morpholine (87 mL, 1003.6 mmol) was added and the reaction mixture was stirred for 18 h.
  • reaction mixture was diluted with 300 mL of water.
  • the organic layer was isolated and washed with water (300 mL) and concentrated in vacuo.
  • the resulting residue was slurried in refluxing EtOAc (150 mL), cooled to rt and filtered.
  • Trichloroisocyanuric acid (65.3 mg, 0.28 mmol) was added in one portion to a solution of 3-(4-bromophenyl)-6-methylpyridazine (Intermediate 64) (200 mg, 0.80 mmol) in DCE (5.9 mL) at rt under air. The reaction mixture was stirred at rt for 30 min. A further 0.15 eq of trichloroisocyanuric acid was added and the reaction mixture was stirred for 30 min.
  • Trichloroisocyanuric acid (65.3 mg, 0.28 mmol) was added in one portion to a solution of 3-(4-bromophenyl)-6-methylpyridazine (Intermediate 64) (200 mg, 0.80 mmol) in DCE (5.5 mL) at rt under air. The reaction mixture was stirred at rt for 30 min. A further 0.15 eq of trichloroisocyanuric acid was added and the reaction mixture was stirred for 30 min. Piperidine (397 ⁇ l, 4.01 mmol) was added and the reaction mixture was stirred at rt for 18 h., then diluted with DCM (20 mL), filtered and concentrated in vacuo.
  • Trichloroisocyanuric acid (65.3 mg, 0.28 mmol) was added in one portion to a solution of 3-(4-bromophenyl)-6-methylpyridazine (Intermediate 64) (200 mg, 0.80 mmol) in DCE (5.5 mL) at rt under air. The reaction mixture was stirred at rt for 30 min. A further 0.15 eq of trichloroisocyanuric acid was added and the reaction mixture was stirred for 30 min. 1-Methylpiperazine (445 ⁇ l, 4.01 mmol) was added and the reaction mixture was stirred at rt for 18 h, then was diluted with DCM (50 mL), filtered and concentrated in vacuo.
  • Trichloroisocyanuric acid (65.3 mg, 0.28 mmol) was added in one portion to a solution of 3-(4-bromophenyl)-6-methylpyridazine (Intermediate 64) (200 mg, 0.80 mmol) in DCE (5.9 mL) at rt under air. The reaction mixture was stirred at rt for 30 min. A further 0.15 eq of trichloroisocyanuric acid was added and the reaction mixture was stirred for 30 min. 1,4-Oxazepane (406 mg, 4.01 mmol) was added and the reaction mixture was stirred at rt for 18 h, then was diluted with DCM (50 mL), filtered and concentrated in vacuo.
  • Trichloroisocyanuric acid (65.3 mg, 0.28 mmol) was added in one portion to a solution of 3-(4-bromophenyl)-6-methylpyridazine (Intermediate 64) (200 mg, 0.80 mmol) in DCE (5.5 mL) at rt under air. The reaction mixture was stirred at rt for 30 min. A further 0.15 eq of trichloroisocyanuric acid was added and the reaction mixture was stirred for 30 min. Azepane (452 ⁇ l, 4.01 mmol) was added and the reaction mixture was stirred at rt for 3 days, then was diluted with DCM (50 mL), filtered and concentrated in vacuo.
  • Pd(Ph 3 P) 4 (135 mg, 0.12 mmol) was added in one portion to a degassed mixture of (4-bromophenyl)boronic acid (470 mg, 2.34 mmol), 4-((5-chloropyrazin-2-yl)methyl)morpholine (500 mg, 2.34 mmol) and 2 M aq. Na 2 CO 3 (2.34 mL, 4.68 mmol) in 1,4-dioxane (7.8 mL) and water (1.5 mL) at rt.
  • reaction mixture was stirred at 80°C for 2 h, then was allowed to cool to rt, diluted with EtOAc (75 mL), and washed sequentially with water (20 mL) and sat. brine (20 mL). The organic layer was dried over MgSO 4 , filtered and concentrated in vacuo.
  • Benzoyl peroxide (0.063 g, 0.26 mmol) was added to 5-bromo-2-methylpyridine (0.9 g, 5.23 mmol), and NBS (0.978 g, 5.49 mmol) in CCl 4 (10 mL) at 15°C.
  • the reaction mixture was heated at reflux for 15 h, then was allowed to cool to rt.
  • the reaction mixture was diluted with DCM (100 mL), and washed sequentially with water (50 mL), and sat. brine (50 mL). The organic layer was dried over Na 2 SO 4 , filtered and concentrated in vacuo.
  • Pd(Ph 3 P) 4 (17 mg, 0.01 mmol) was added to 1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazine (sourced commercially) (95 mg, 0.30 mmol), ( R )-6-((1-(5-bromopyridin-2-yl)pyrrolidin-3-yl)methyl)-2,5,7-trimethyl-[1,2,4]triazolo[1,5-a]pyrimidine (Intermediate 5) (120 mg, 0.30 mmol) and Na 2 CO 3 (63.4 mg, 0.60 mmol) in 1,4-dioxane (3 mL) and water (1.5 mL) at rt.
  • XPhos 2 nd generation precatalyst 34 mg, 0.04 mmol was added to rac-6-((1-(5-bromopyrimidin-2-yl)pyrrolidin-3-yl)methyl)-2,5,7-trimethyl-[1,2,4]triazolo[1,5-a]pyrimidine (Intermediate 10) (350 mg, 0.87 mmol), 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)morpholine (sourced commercially) (264 mg, 0.87 mmol) and Cs 2 CO 3 (567 mg, 1.74 mmol) in 1,4-dioxane (3 mL) and water (1.5 mL) at rt.
  • the reaction mixture was stirred at 80°C for 16 h, then was allowed to cool to rt and was concentrated in vacuo.
  • the resulting crude product was purified by flash C18 chromatography, eluting with 5-100% MeCN in water (+0.08% NH 4 CO 3 ).
  • Pd(Ph 3 P) 4 (46.1 mg, 0.04 mmol) was added to 4-((5-chloropyrazin-2-yl)methyl)morpholine (Intermediate 76) (85 mg, 0.40 mmol), ( R )-6-((1-(6-bromopyridin-3-yl)pyrrolidin-3-yl)methyl)-2,5,7-trimethyl-[1,2,4]triazolo[1,5-a]pyrimidine (Intermediate 12) (160 mg, 0.40 mmol) and 1,1,1,2,2,2-hexamethyldistannane (131 mg, 0.40 mmol) in 1,4-dioxane (5 mL) at rt.
  • Pd(Ph 3 P) 4 (343 mg, 0.30 mmol) was added in one portion to 4-((6-chloropyridazin-3-yl)methyl)morpholine (Intermediate 14) (634 mg, 2.97 mmol), ( R )-6-((1-(6-bromopyridin-3-yl)pyrrolidin-3-yl)methyl)-2,5,7-trimethyl-[1,2,4]triazolo[1,5-a]pyrimidine (Intermediate 12) (1.19 g, 2.97 mmol) and 1,1,1,2,2,2-hexamethyldistannane (0.615 mL, 2.97 mmol) in 1,4-dioxane (30 mL) at rt.
  • reaction mixture was stirred at 100°C for 20 h, then allowed to cool to rt, filtered and washed with DCM (20 mL). The filtrate was concentrated in vacuo and the resulting crude product was purified by fcc, eluting with 0-10% 1 M NH 3 / MeOH in DCM, then further purified by preparative HPLC, then dissolved in MeOH and loaded onto a 50g SCX column. The column was washed with MeOH (2 ⁇ column volumes) then eluted with 1 M NH 3 / MeOH.
  • Example 10 6-((( R )-1-(2-(4-(((S)-2,4-dimethylpiperazin-1-yl)methyl)phenyl)pyrimidin-5-yl)pyrrolidin-3-yl)methyl)-2,5,7-trimethyl-[1,2,4]triazolo[1,5-a]pyrimidine
  • the reaction mixture allowed to cool to rt, then poured into DCM (50 mL). The aqueous layer was separated then extracted with 20% MeOH/DCM. The combined organic layers were dried over MgSO 4 , filtered and concentrated in vacuo. The resulting crude product was purified by fcc, eluting with 0-5% 1 M NH 3 / MeOH in DCM.
  • PdCl 2 (dppf)-CH 2 Cl 2 adduct (168 mg, 0.21 mmol) was added to 2-(4-(4-bromobenzyl)piperazin-1-yl)-N,N-dimethylacetamide (Intermediate 22) (700 mg, 2.06 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (627 mg, 2.47 mmol) and potassium acetate (404 mg, 4.11 mmol) in 1,4-dioxane (10 mL) at rt.
  • Pd(Ph 3 P) 4 (31.6 mg, 0.03 mmol) was added to (4-((4-(2-(dimethylamino)-2-oxoethyl)piperazin-1-yl)methyl)phenyl)boronic acid (92 mg, 0.30 mmol), (R)-6-((1-(2-bromopyrimidin-5-yl)pyrrolidin-3-yl)methyl)-2,5,7-trimethyl-[1,2,4]triazolo[1,5-a]pyrimidine (Intermediate 16) (110 mg, 0.27 mmol) and Na 2 CO 3 (58.0 mg, 0.55 mmol) in 1,4-dioxane (2 mL) and water (1 mL) at rt.
  • Pd(Ph 3 P) 4 (31.6 mg, 0.03 mmol) was added to (4-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)phenyl)boronic acid (87 mg, 0.33 mmol), ( R )-6-((1-(2-bromopyrimidin-5-yl)pyrrolidin-3-yl)methyl)-2,5,7-trimethyl-[1,2,4]triazolo[1,5-a]pyrimidine (Intermediate 16) (110 mg, 0.27 mmol) and Na 2 CO 3 (58.0 mg, 0.55 mmol) in 1,4-dioxane (2 mL) and water (1 mL) at rt.
  • RuPhos 3rd generation precatalyst 50 mg, 0.06 mmol was added to 4-(4-(5-bromopyrimidin-2-yl)benzyl)morpholine (Intermediate 24) (200 mg, 0.60 mmol), (R)-2,5,7-trimethyl-6-(pyrrolidin-3-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrimidine.2HCl (Intermediate 4) (190 mg, 0.60 mmol), Cs 2 CO 3 (780 mg, 2.39 mmol) and RuPhos (55.8 mg, 0.12 mmol) in 1,4-dioxane (8 mL) at rt.
  • RuPhos 3rd generation precatalyst 39 mg, 0.05 mmol was added to (R)-2,5,7-trimethyl-6-(pyrrolidin-3-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrimidine dihydrochloride (Intermediate 4) (150 mg, 0.47 mmol), 4-((6-(4-bromophenyl)pyridin-3-yl)methyl)morpholine (Intermediate 31) (157 mg, 0.47 mmol), Cs 2 CO 3 (768 mg, 2.36 mmol) and RuPhos (44 mg, 0.09 mmol) in 1,4-dioxane (3 mL) at rt.
  • RuPhos 3rd generation precatalyst 36 mg, 0.04 mmol
  • RuPhos (20 mg, 0.04 mmol) was added to 2-(4-bromophenyl)-5-((4-methylpiperazin-1-yl)methyl)pyrimidine (Intermediate 35) (150 mg, 0.43 mmol), ( R )-2,5,7-trimethyl-6-(pyrrolidin-3-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrimidine dihydrochloride (Intermediate 4) (137 mg, 0.43 mmol) and Cs 2 CO 3 (563 mg, 1.73 mmol) in 1,4-dioxane (5mL).
  • RuPhos 3rd generation precatalyst (53 mg, 0.06 mmol) was added to (R)-2,5,7-trimethyl-6-(pyrrolidin-3-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrimidine dihydrochloride (Intermediate 4) (200 mg, 0.63 mmol), 4-((5-(4-bromophenyl)pyrimidin-2-yl)methyl)morpholine (Intermediate 39) (231 mg, 0.69 mmol), Cs 2 CO 3 (819 mg, 2.51 mmol) and Ruphos (59 mg, 0.13 mmol) in 1,4-dioxane (8 mL).
  • the reaction mixture was heated at 90°C for 6 h, allowed to cool to rt, diluted with DCM (50 mL) and filtered. The filtrate was concentrated in vacuo.
  • the resulting crude product was purified by fcc, eluting with 0-5% 1 M NH 3 /MeOH in DCM.
  • Example 30 was prepared in a similar way to Example 29 in 5 steps from commercially available (S)-tert-butyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate to afford the title compound (122 mg, 30% final step) as a white solid; 1 H NMR (500 MHz, DMSO) 1.86 (1H, dq), 2.07 - 2.16 (1H, m), 2.38 - 2.45 (4H, m), 2.47 (3H, s), 2.59 (1H, d), 2.64 (3H, s), 2.74 (3H, s), 2.93 (2H, d), 3.09 (1H, dd), 3.32 (1H, d), 3.43 (1H, dd), 3.46 - 3.53 (1H, m), 3.54 - 3.63 (4H, m), 3.75 (2H, s), 6.65 (2H, d), 7.62 (1H, d), 7.98 (2H, d), 8.02 (1H, d); m / z MH + 499.
  • (2S,6R)-1,2,6-trimethylpiperazine (sourced commercially) (104 mg, 0.81 mmol) was added in one portion to (R)-6-((1-(5-(4-(chloromethyl)phenyl)pyrazin-2-yl)pyrrolidin-3-yl)methyl)-2,5,7-trimethyl-[1,2,4]triazolo[1,5-a]pyrimidine (Intermediate 48) (181 mg, 0.40 mmol) and triethylamine (0.28 mL, 2.02 mmol) in THF (5 mL) at rt under air.
  • reaction mixture was stirred at 60°C for 24 h, allowed to cool to rt, and diluted with EtOAc (50 mL) and water (15 mL). The organic layer was isolated and washed with sat. brine (15 mL), dried over MgSO 4 , filtered and concentrated in vacuo.
  • Example 33 6-(((R)-1-(5-(4-(((R)-3,4-dimethylpiperazin-1-yl)methyl)phenyl)pyrazin-2-yl)pyrrolidin-3-yl)methyl)-2,5,7-trimethyl- [1,2,4] triazolo [1,5-a] pyrimidine
  • Example 34 6-(((R)-1-(5-(4-(((R)-2,4-dimethylpiperazin-1-yl)methyl)phenyl)pyrazin-2-yl)pyrrolidin-3-yl)methyl)-2,5,7-trimethyl- [1,2,4] triazolo [1,5-a] pyrimidine
  • reaction mixture was stirred at 80°C for 24 h, allowed to cool to rt and diluted with EtOAc (50 mL) and water (15 mL). The organic layer was isolated and washed with sat. brine (15 mL), dried over MgSO 4 , filtered and concentrated in vacuo.
  • (2R,5R)-1,2,5-trimethylpiperazine hydrochloride (sourced commercially) (147 mg, 0.89 mmol) was added in one portion to (R)-6-((1-(5-(4-(chloromethyl)phenyl)pyrazin-2-yl)pyrrolidin-3-yl)methyl)-2,5,7-trimethyl-[1,2,4]triazolo[1,5-a]pyrimidine (Intermediate 48) (200 mg, 0.45 mmol) and triethylamine (0.31 mL, 2.23 mmol) in 1,4-dioxane (5 mL) at rt under air.
  • reaction mixture was stirred at 80°C for 24 h, allowed to cool to rt and diluted with EtOAc (50 mL) and water (15 mL). The organic layer was isolated and washed with sat. brine solution (15 ml), dried over MgSO 4 , filtered and dried in vacuo.
  • (2R,5S)-1,2,5-trimethylpiperazine dihydrochloride (sourced commercially) (180 mg, 0.89 mmol) was added in one portion to (R)-6-((1-(5-(4-(chloromethyl)phenyl)pyrazin-2-yl)pyrrolidin-3-yl)methyl)-2,5,7-trimethyl-[1,2,4]triazolo[1,5-a]pyrimidine (Intermediate 48) (200 mg, 0.45 mmol) and triethylamine (0.31 mL, 2.23 mmol) in 1,4-dioxane (5 mL) at rt under air.
  • reaction mixture was stirred at 80°C for 24 h, allowed to cool to rt and diluted with EtOAc (50 mL) and water (15 mL). The organic layer was isolate and washed with sat. brine solution (15 mL), dried over MgSO 4 , filtered and concentrated in vacuo.
  • Example 40 6-(((R)-1-(5-(4-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)pyrazin-2-yl)pyrrolidin-3-yl)methyl)-2,5,7-trimethyl-[1,2,4]triazolo[1,5-a]pyrimidine
  • Example 48 6-(((R)-1-(5-(4-(((S)-3,4-dimethylpiperazin-1-yl)methyl)phenyl)pyrazin-2-yl)pyrrolidin-3-yl)methyl)-2,5,7-trimethyl-[1,2,4]triazolo[1,5-a]pyrimidine
  • Example 50 6-(((R)-1-(5-(4-(((S)-2,4-dimethylpiperazin-1-yl)methyl)phenyl)pyrazin-2-yl)pyrrolidin-3-yl)methyl)-2,5,7-trimethyl-[1,2,4]triazolo[1,5-a]pyrimidine
  • reaction mixture was stirred at 80°C for 24 h, allowed to cool to rt and diluted with EtOAc (50 mL) and water (15 mL). The organic layer was isolated and washed with sat. brine (15 mL), dried over MgSO 4 , filtered and concentrated in vacuo.
  • XPhos 2 nd generation precatalyst (11.3 mg, 0.01 mmol) was added to 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)morpholine (sourced commercially) (87 mg, 0.29 mmol), (R)-6-((1-(5-bromo-6-methylpyrazin-2-yl)pyrrolidin-3-yl)methyl)-2,5,7-trimethyl-[1,2,4]triazolo[1,5-a]pyrimidine (Intermediate 45) (120 mg, 0.29 mmol) and Cs 2 CO 3 (188 mg, 0.58 mmol) in 1,4-dioxane (4 mL) and water (1.5 mL).
  • XPhos 2 nd generation precatalyst (59 mg, 0.07 mmol) was added and the reaction mixture was stirred for 18 h at 90°C, then allowed to cool to rt and diluted with EtOAc (50 mL). The organic layer was isolated and washed with sat. brine solution and dried over MgSO 4 , filtered and concentrated in vacuo. The resulting crude product was purified by fcc, eluting with 0-4% 1 M NH 3 /MeOH in DCM.
  • the reaction mixture was heated at 90°C for 3 h, allowed to cool to rt and concentrated in vacuo.
  • the residue was taken up in water (1 L) and extracted with DCM (3 x 800 mL). The combined organic layers were washed with water, sat. brine, dried over MgSO 4 , filtered and concentrated in vacuo.
  • the resulting crude product was purified by fcc, eluting with 0-15% MeOH in DCM.
  • the product was taken up in MeCN (150ml) and stirred for 2 h after sonication.
  • Form A is characterised by at least one peak at a 2 ⁇ value of 7.8° or 19.0°, measured using CuKa radiation. The ten most prominent peaks of the XRPD are shown in Table A.
  • 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione (2.8 Kg, 12.05 mol) was added portionwise to 3-(4-bromophenyl)-6-methylpyridazine (Intermediate 64) (7.15 Kg, 27.32 mol) in DCM (338.35 L) at rt.
  • the reaction mixture was stirred at rt for 3 h then a further portion of 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione (0.31 Kg, 1.33 mol) was added and the reaction mixture was stirred for 3 h at rt.
  • reaction mixture was filtered, and the organic filtrate was washed with water (68 L) before a solvent swap into acetonitrile (55 L).
  • Morpholine (4.75 Kg, 54.52 mol) was added and the mixture heated for 4 h before concentration and filtration to give a solid which was washed with acetonitrile (6 L) and water (6 L).
  • the solid was dissolved using 4N hydrochloric acid (7.5 Kg) and water (45 L).
  • the acidic solution was washed with ethyl acetate (2 x 2.5 L) before pH adjustment with 15% w/w sodium hydroxide (11 Kg) to give a solid which was isolated by filtration.
  • Aminoguananidine bicarbonate (17.7 Kg, 130.04 mol) was mixed with nitric acid (165 g, 2.62 mol) in acetic acid (29.8 L, 521.21 mol) for 64 h at 90°C. The mixture was cooled and diluted with isopropyl acetate (30 L) and filtered to afford the title compound. The crude material (13.9 Kg, 36.7% yield based on 33.7% w/w assay) was used directly in stage 5.
  • the resulting DCM solution is passed through a silica thiol resin (0.5 Kg) before solvent swapping into ethyl acetate to give 5 Kg of crude material.
  • Example 63 was prepared in a similar way to Example 62 in 3 steps from commercially available tert- butyl ( R )-3-hydroxypyrrolidine-1-carboxylate to afford the title compound (125 mg, 31% final step) as a white solid; 1 H NMR (400 MHz, DMSO) 2.26 - 2.47 (9H, m), 2.52 (3H, s), 2.58 (3H, s), 3.45 (1H, dd), 3.5 - 3.61 (6H, m), 3.61 - 3.69 (1H, m), 3.77 (2H, s), 4.96 (1H, s), 6.73 (2H, d), 7.64 (1H, d), 8.04 (3H, dd); m / z MH + 501.
  • the reaction was degassed and RuPhos 3rd generation precatalyst (38 mg, 0.05 mmol) and RuPhos (21 mg, 0.05 mmol) were added.
  • the reaction mixture was heated at reflux for 18 h, allowed to cool to rt and then diluted with DCM (10 mL) and water (5 mL) and passed through a phase separating cartridge. The resulting DCM layer was concentrated in vacuo.
  • Example 65 ( R )-2,5,7-trimethyl-6-((1-(4-(6-((4-methylpiperazin-1-yl)methyl)pyridazin-3-yl)phenyl)pyrrolidin-3-yl)oxy)-[1,2,4]triazolo[1,5-a]pyrimidine
  • the reaction was degassed and RuPhos 3rd generation precatalyst (38 mg, 0.05 mmol) and RuPhos (21 mg, 0.05 mmol) were added.
  • the reaction mixture was heated at reflux for 18 h, allowed to cool to rt and then diluted with DCM (10 mL) and water (5 mL) and passed through a phase separating cartridge. The resulting DCM layer was concentrated in vacuo.
  • Example 66 2,5,7-trimethyl-6-(((3 R )-1-(4-(6-((3-methyl-3,8-diazabicyclo[3.2.1]octan-8-yl)methyl)pyridazin-3-yl)phenyl)pyrrolidin-3-yl)oxy)-[1,2,4]triazolo[1,5-a]pyrimidine
  • the reaction was degassed and RuPhos 3rd generation precatalyst (31.7 mg, 0.04 mmol) and RuPhos (17.69 mg, 0.04 mmol) were added.
  • the reaction mixture was heated at reflux for 18 h, allowed to cool to rt then diluted with DCM (10 mL) and water (5 mL) and passed through a phase separating cartridge. The resulting DCM layer was concentrated in vacuo.
  • Example 67 6-((( R )-1-(4-(6-((( R )-hexahydropyrrolo[1,2-a]pyrazin-2(1 H )-yl)methyl)pyridazin-3-yl)phenyl)pyrrolidin-3-yl)oxy)-2,5,7-trimethyl-[1,2,4]triazolo[1,5-a]pyrimidine
  • the reaction was degassed and RuPhos 3rd generation precatalyst (31.7 mg, 0.04 mmol) and RuPhos (17.7 mg, 0.04 mmol) were added.
  • the reaction mixture was heated at reflux for 18 h, allowed to cool to rt and then diluted with DCM (10 mL) and water (5 mL) and passed through a phase separating cartridge. The resulting DCM layer was concentrated in vacuo.
  • Example 68 6-((( R )-1-(4-(6-((( S )-hexahydropyrrolo[1,2-a]pyrazin-2(1 H )-yl)methyl)pyridazin-3-yl)phenyl)pyrrolidin-3-yl)oxy)-2,5,7-trimethyl-[1,2,4]triazolo[1,5-a]pyrimidine
  • the reaction was degassed and RuPhos 3rd generation precatalyst (31.7 mg, 0.04 mmol) and RuPhos (17.7 mg, 0.04 mmol) were added.
  • the reaction mixture was heated at reflux for 18 h, allowed to cool to rt, then diluted with DCM (10 mL) and water (5 mL) and passed through a phase separating cartridge. The resulting DCM layer was concentrated in vacuo.
  • the reaction was degassed and RuPhos 3rd generation precatalyst (25.7 mg, 0.03 mmol) and RuPhos (14.4 mg, 0.03 mmol) were added.
  • the reaction mixture was heated at reflux for 18 h, allowed to cool to rt, then diluted with DCM (10 mL) and water (5 mL) and passed through a phase separating cartridge. The resulting DCM layer was concentrated in vacuo.
  • the reaction was degassed and RuPhos 3rd generation precatalyst (42.9 mg, 0.05 mmol) and RuPhos (23.9 mg, 0.05 mmol) were added.
  • the reaction mixture was heated at reflux for 18 h, allowed to cool to rt, then diluted with DCM (10 mL) and water (5 mL) and passed through a phase separating cartridge. The resulting DCM layer was concentrated in vacuo.
  • the reaction was degassed and RuPhos 3rd generation precatalyst (40.6 mg, 0.05 mmol) and RuPhos (22.6 mg, 0.05 mmol) were added.
  • the resulting suspension was heated at reflux for 18 h, allowed to cool to rt, diluted with DCM (10 mL) and water (5 mL) and passed through a phase separating cartridge. The resulting DCM layer was concentrated in vacuo.
  • Example 72 ( R )-6-((1-(4-(6-((4-ethylpiperazin-1-yl)methyl)pyridazin-3-yl)phenyl)pyrrolidin-3-yl)oxy)-2,5,7-trimethyl-[1,2,4]triazolo[1,5-a]pyrimidine
  • the reaction was degassed and RuPhos 3rd generation precatalyst (21.6 mg, 0.03 mmol) and RuPhos (12.0 mg, 0.03 mmol) were added.
  • the reaction mixture was heated at reflux for 18 h, allowed to cool to rt, diluted with DCM (10 mL) and water (5 mL) and passed through a phase separating cartridge. The resulting DCM layer was concentrated in vacuo.
  • the reaction was degassed and RuPhos 3rd generation precatalyst (55.8 mg, 0.07 mmol) and RuPhos (31.1 mg, 0.07 mmol) were added.
  • the reaction mixture was heated at reflux for 18 h, allowed to cool to rt, diluted with DCM (10 mL) and water (5 mL) and passed through a phase separating cartridge. The resulting DCM layer was concentrated in vacuo.
  • reaction mixture was heated at reflux for 1 h, allowed to cool to r, diluted with EtOAc (50 mL) and washed with water (50 mL). The organic layer was isolated and dried over MgSO 4 , filtered and concentrated in vacuo.
  • reaction mixture was heated at reflux for 1 h, allowed to cool to rt, diluted with EtOAc (50 mL) and washed with water (50 mL). The organic layer was isolated and dried over MgSO 4 , filtered and concentrated in vacuo.
  • Example 79 1-[4-[[4-[5-[(3 R )-3-[(2,5,7-trimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)methyl]pyrrolidin-1-yl]pyrazin-2-yl]phenyl]methyl]-1,4-diazepan-1-yl]ethanone
  • Example 80 ( R )-2,5,7-trimethyl-6-((1-(5-(4-(pyrrolidin-1-ylmethyl)phenyl)pyrazin-2-yl)pyrrolidin-3-yl)methyl)-[1,2,4]triazolo[1,5-a]pyrimidine
  • reaction mixture was transferred to a microwave vial and ( R )-6-((1-(5-bromopyrazin-2-yl)pyrrolidin-3-yl)methyl)-2,5,7-trimethyl-[1,2,4]triazolo[1,5-a]pyrimidine (300 mg, 0.75 mmol) and Pd(Ph 3 P) 4 (86 mg, 0.07 mmol) were added.
  • the reaction mixture was heated at 100°C for 5 h in a microwave reactor then allowed to cool to rt.
  • Example 82 ( R )-2,5,7-trimethyl-6-((1-(5-(6-(pyrrolidin-1-ylmethyl)pyridin-3-yl)pyrazin-2-yl)pyrrolidin-3-yl)methyl)-[1,2,4]triazolo[1,5-a]pyrimidine
  • PdCl 2 (dppf)-CH 2 Cl 2 adduct 85 mg, 0.12 mmol was added to 5-bromo-2-(pyrrolidin-1-ylmethyl)pyridine (Intermediate 80) (560 mg, 2.32 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (590 mg, 2.32 mmol) and potassium acetate (456 mg, 4.64 mmol) in 1,4-dioxane (10 mL) at rt. The reaction mixture was stirred at 90°C for 16 h, and allowed to cool to rt.
  • reaction mixture was purified by flash C18 chromatography, eluting with 5-100% MeOH in water to afford impure 2-(pyrrolidin-1-ylmethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (280 mg, 42% if pure) as a yellow solid.
  • the reaction was degassed and RuPhos 3rd generation precatalyst (35.5 mg, 0.04 mmol) and RuPhos (19.8 mg, 0.04 mmol) were added.
  • the reaction mixture was stirred at 88°C for 18 h, allowed to cool to rt, diluted with DCM (10 mL) and water (5 mL) and passed through a phase separating cartridge. The resulting DCM layer was concentrated in vacuo.
  • the reaction was degassed and RuPhos 3rd generation precatalyst (16 mg, 0.02 mmol) and RuPhos (9 mg, 0.02 mmol) were added.
  • the reaction mixture was stirred at 88°C for 18 h, allowed to cool to rt, diluted with DCM (10 mL) and water (5 mL) and passed through a phase separating cartridge. The resulting DCM layer was concentrated in vacuo.
  • the resulting crude product was dissolved in DMSO (2 mL) and purified by preparative HPLC.
  • Examples 86 and 87 4-[(1R)-1-[4-[5-[(3R)-3-[(2,5,7-trimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)oxy]pyrrolidin-1-yl]pyrazin-2-yl]phenyl]ethyl]morpholine and 4-[(1S)-1-[4-[5-[(3R)-3-[(2,5,7-trimethyl-[1,2,4]triazolo[1,5-a] pyrimidin-6-yl)oxy] pyrrolidin-1-yl] pyrazin-2-yl]phenyl] ethyl] morpholine
  • Tetrakis(triphenylphosphine)palladium(0) (157 mg, 0.14 mmol) was added to a degassed solution of 4-(1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)morpholine (sourced commercially) (432 mg, 1.36 mmol), ( R )-6-((1-(5-bromopyrazin-2-yl)pyrrolidin-3-yl)oxy)-2,5,7-trimethyl-[1,2,4]triazolo[1,5-a]pyrimidine (Intermediate 62) (550 mg, 1.36 mmol) and sodium carbonate (2.0 mL, 4.1 mmol) in 1,4-dioxane (7.7 mL) and water (3.9 mL) under nitrogen.
  • the resulting solution was stirred at 80°C for 2 hours then allowed to cool to rt.
  • the reaction mixture was diluted with EtOAc (50 mL), and washed sequentially with water (25 mL) and sat. brine (25 mL).
  • the organic layer was dried over MgSO 4 , filtered and concentrated in vacuo.
  • the resulting crude product was purified by fcc, elution gradient 0-5% MeOH in DCM, to afford the title compound as a mixture of two diastereomers (355 mg).
  • the isomers were isolated by chiral SFC (Phenomonex C1, 30 x 250 mm, 5 micron column at a flow rate of 80ml/min using 40% IPA + 0.1% DEA / 60% scCO 2 at 120 bar and column temperature of 40 °C) to afford a single diastereomer (unknown chirality alpha to morpholine) of 4-(1-(4-(5-((R)-3-((2,5,7-trimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)oxy)pyrrolidin-1-yl)pyrazin-2-yl)phenyl)ethyl)morpholine (62 mg, 18%); 1 H NMR (400 MHz, CDCl 3 ) 1.38 (3H, d), 2.28 - 2.47 (3H, m), 2.47 - 2.58 (3H, m), 2.60 (3H, s), 2.62 (3H, s), 2.66 (3H, s), 3.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP19723404.0A 2018-05-11 2019-05-10 Triazolopyrimidine compounds and their use in treating cancer Active EP3790879B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP22181542.6A EP4134368A1 (en) 2018-05-11 2019-05-10 Triazolopyrimidine compounds and their use in treating cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862670075P 2018-05-11 2018-05-11
PCT/EP2019/062020 WO2019215316A1 (en) 2018-05-11 2019-05-10 Triazolopyrimidine compounds and their use in treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP22181542.6A Division EP4134368A1 (en) 2018-05-11 2019-05-10 Triazolopyrimidine compounds and their use in treating cancer

Publications (2)

Publication Number Publication Date
EP3790879A1 EP3790879A1 (en) 2021-03-17
EP3790879B1 true EP3790879B1 (en) 2022-06-29

Family

ID=66484070

Family Applications (2)

Application Number Title Priority Date Filing Date
EP19723404.0A Active EP3790879B1 (en) 2018-05-11 2019-05-10 Triazolopyrimidine compounds and their use in treating cancer
EP22181542.6A Pending EP4134368A1 (en) 2018-05-11 2019-05-10 Triazolopyrimidine compounds and their use in treating cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP22181542.6A Pending EP4134368A1 (en) 2018-05-11 2019-05-10 Triazolopyrimidine compounds and their use in treating cancer

Country Status (16)

Country Link
US (3) US11084827B2 (zh)
EP (2) EP3790879B1 (zh)
JP (1) JP7418353B2 (zh)
KR (1) KR20210013078A (zh)
CN (3) CN115028636A (zh)
AR (1) AR115384A1 (zh)
AU (1) AU2019264826B2 (zh)
BR (1) BR112020023068A2 (zh)
CA (1) CA3099579A1 (zh)
DK (1) DK3790879T3 (zh)
ES (1) ES2927244T3 (zh)
MX (1) MX2020012058A (zh)
PT (1) PT3790879T (zh)
TW (1) TWI823932B (zh)
UY (1) UY38228A (zh)
WO (1) WO2019215316A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021228286A1 (en) * 2020-02-28 2022-10-06 Remix Therapeutics Inc. Pyridazine derivatives for modulating nucleic acid splicing
WO2021236893A1 (en) * 2020-05-21 2021-11-25 Teon Therapeutics, Inc. Monocarboxylic acid transporter 4 (mct4) modulators and uses thereof
WO2021249969A1 (en) * 2020-06-10 2021-12-16 Merck Patent Gmbh Combination product for the treatment of cancer diseases
AU2021372815A1 (en) 2020-11-02 2023-06-22 Ares Trading S.A. Combination treatment of cancer
US20240270749A1 (en) 2021-05-21 2024-08-15 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 1,2,4-triazolo[1,5-a]pyrimidine-based slc16a3 inhibitors and their therapeutic use
WO2022243574A1 (en) 2021-05-21 2022-11-24 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 3-(phthalazin-1-yl)benzenesulfonamide-based slc16a3 inhibitors and their therapeutic use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072746A1 (en) * 2001-10-16 2004-04-15 Michael Sullivan Inhibitors of monocarboxylate transport
SE0300119D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
DE102005034905A1 (de) 2005-07-26 2007-02-01 Federal-Mogul Nürnberg GmbH Verfahren zur Herstellung eines Kolbens für einen Verbrennungsmotor sowie Kolben für einen Verbrennungsmotor
WO2010089580A1 (en) 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
WO2011114148A1 (en) 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
WO2016118825A1 (en) * 2015-01-22 2016-07-28 The Scripps Research Institute Heterocyclic inhibitors of monocarboxylate transporters
US10328078B2 (en) * 2015-01-22 2019-06-25 The Scripps Research Institute Pteridine dione monocarboxylate transporter inhibitors
EP3307068B1 (en) * 2015-06-12 2021-08-25 Vettore, LLC Mct4 inhibitors for treating disease
WO2017196936A1 (en) * 2016-05-12 2017-11-16 Regents Of The University Of Minnesota Indole and indazole cyanocinnamate compounds and therapeutic uses thereof

Also Published As

Publication number Publication date
PT3790879T (pt) 2022-08-26
CN112469721A (zh) 2021-03-09
WO2019215316A1 (en) 2019-11-14
KR20210013078A (ko) 2021-02-03
US11084827B2 (en) 2021-08-10
US20210340150A1 (en) 2021-11-04
MX2020012058A (es) 2021-02-26
DK3790879T3 (da) 2022-08-29
US20210087196A1 (en) 2021-03-25
AU2019264826A1 (en) 2020-11-26
US11851432B2 (en) 2023-12-26
CN115028636A (zh) 2022-09-09
TW202015674A (zh) 2020-05-01
AU2019264826B2 (en) 2024-05-23
CA3099579A1 (en) 2019-11-14
JP2021523177A (ja) 2021-09-02
AR115384A1 (es) 2021-01-13
JP7418353B2 (ja) 2024-01-19
US20240217980A1 (en) 2024-07-04
ES2927244T3 (es) 2022-11-03
TWI823932B (zh) 2023-12-01
CN112469721B (zh) 2022-06-07
CN115028637B (zh) 2024-03-22
EP4134368A1 (en) 2023-02-15
CN115028637A (zh) 2022-09-09
BR112020023068A2 (pt) 2021-02-09
EP3790879A1 (en) 2021-03-17
UY38228A (es) 2019-10-31

Similar Documents

Publication Publication Date Title
EP3790879B1 (en) Triazolopyrimidine compounds and their use in treating cancer
US11884671B2 (en) Purinone compounds and their use in treating cancer
EP3140303B1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
EP3060550B1 (en) Heteroaryl compounds as btk inhibitors and uses thereof
EP3683220A1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of huntigton's disease
AU2020252116B2 (en) Estrogen receptor degrading protacs
EP2935271B1 (en) Novel substituted imidazoles as casein kinase 1 / inhibitors
EP3053923B1 (en) Triazolopyrazine derivatives as tyrosin kinase inhibitors
EP3947375B1 (en) Imidazolonylquinoline compounds and therapeutic uses thereof
EP4289835A1 (en) Cdk inhibitor
WO2019057757A1 (en) 1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
RU2793249C2 (ru) Триазолпиримидиновые соединения и их применение в лечении рака
WO2022263604A1 (en) Substituted pyrazolo[1,5-a]pyrimidine-7-amine compounds as cdk inhibitors and their therapeutic use
CN117693503A (zh) 作为hpk1抑制剂用于治疗癌症的经取代的吡嗪-2-甲酰胺

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201208

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40047025

Country of ref document: HK

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20220114

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1501299

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220715

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602019016447

Country of ref document: DE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3790879

Country of ref document: PT

Date of ref document: 20220826

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20220822

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20220824

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20220629

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220930

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220929

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2927244

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20221103

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221029

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602019016447

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20230330

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230513

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1501299

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220629

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20230531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230510

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240315

Year of fee payment: 6

Ref country code: IE

Payment date: 20240312

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240321

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20240312

Year of fee payment: 6

Ref country code: FR

Payment date: 20240308

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240313

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20240515

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240602

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240610

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20240425

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NO

Payment date: 20240508

Year of fee payment: 6

Ref country code: IT

Payment date: 20240411

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20240502

Year of fee payment: 6